cynata1000false10/2ff99.13.08.01InitialDirector.pdf2018-11-04T23:51:18.000Z"ee46fb7ff2fe710bc0febde13b1ab35b"14100STANDARD10/conversions/2ff99.13.08.01InitialDirector-thumb.jpg2018-11-06T05:47:20.000Z"7935bda639f393329882e24e57387485"4941STANDARD100/3e823.14.05.22.Appendix3Y-Ross.pdf2018-11-04T23:51:40.000Z"5dc4926e47669254e19e64880179a489"24272STANDARD100/conversions/3e823.14.05.22.Appendix3Y-Ross-thumb.jpg2018-11-05T09:21:36.000Z"4a35b7e4df97a6fca4821a2cbe341d26"12987STANDARD101/4fdd5.14.05.22.Appendix3Y-Stew.pdf2018-11-04T23:51:41.000Z"0897e6609eaed4fdc8c4e0c5db34b7d5"25259STANDARD101/conversions/4fdd5.14.05.22.Appendix3Y-Stew-thumb.jpg2018-11-05T09:21:37.000Z"625e2cfe713d59ce60e78cbe422966f0"13743STANDARD102/5de0b.14.05.29.Appendix3B-Issu.pdf2018-11-04T23:51:41.000Z"f5013eaff46eacaed74dde65002eb078"180648STANDARD102/conversions/5de0b.14.05.29.Appendix3B-Issu-thumb.jpg2018-11-05T09:21:38.000Z"09fd46c8c9de47e277495e80de590c16"10529STANDARD103/0da94.14.06.02.LeadingBrokerag.pdf2018-11-04T23:51:41.000Z"7bac1fc6bf4927a94f7065c75118400c"142568STANDARD103/conversions/0da94.14.06.02.LeadingBrokerag-thumb.jpg2018-11-05T09:21:39.000Z"3905ecf50f84efeb13d8ab163afa2578"12069STANDARD104/b172c.14.06.11.CynataAnnounces.pdf2018-11-04T23:51:41.000Z"58235579691cabe6a823a67d2465220b"474431STANDARD104/conversions/b172c.14.06.11.CynataAnnounces-thumb.jpg2018-11-05T09:21:40.000Z"71733341b260f9f2850fd42c81ae9d0c"15420STANDARD105/0cdc2.14.07.14.LeadingCROtoC.pdf2018-11-04T23:51:41.000Z"a30f911651b9f3e5c8645aa0e3a2144c"71361STANDARD105/conversions/0cdc2.14.07.14.LeadingCROtoC-thumb.jpg2018-11-05T09:21:41.000Z"9625d15751aeaf95c13f6d93cdae349d"19891STANDARD106/81650.14.07.28.CYPContractsUW.pdf2018-11-04T23:51:42.000Z"976ae454903558a782aff5b52427238e"150501STANDARD106/conversions/81650.14.07.28.CYPContractsUW-thumb.jpg2018-11-05T09:21:42.000Z"743d1813df901df6158e54f8c908ded7"19327STANDARD107/2072c.14.07.31.ActivitiesRepor.pdf2018-11-04T23:51:42.000Z"1b1efa3fa01aeba8b976ff4451d49f63"280044STANDARD107/conversions/2072c.14.07.31.ActivitiesRepor-thumb.jpg2018-11-05T09:21:43.000Z"a3b90ee2126cfadab349d02c474f6833"17687STANDARD108/conversions/f9af9.14.08.26.Appendix4EFi-thumb.jpg2018-11-05T09:21:44.000Z"f047593319d861646859af1921ee4a27"14158STANDARD108/f9af9.14.08.26.Appendix4EFi.pdf2018-11-04T23:51:42.000Z"399d818eaad653e2ba68f6fd97fd4f41"4528935STANDARD109/4c07d.14.09.03.CynataResponds.pdf2018-11-04T23:51:45.000Z"feeff4004874752e7c601becd310d45f"143868STANDARD109/conversions/4c07d.14.09.03.CynataResponds-thumb.jpg2018-11-05T09:21:45.000Z"5dfd1ab21c5ff3cc87d31596b2625461"13127STANDARD11/2d79a.13.08.01FinalDirectors.pdf2018-11-04T23:51:18.000Z"63c4102033dfad2e9642190ac4be6c13"12856STANDARD11/conversions/2d79a.13.08.01FinalDirectors-thumb.jpg2018-11-06T05:47:20.000Z"5489b954156e2dd1cb25ddb26b808fd7"4995STANDARD110/conversions/e7281.14.09.03.CynataInitiates-thumb.jpg2018-11-05T09:21:46.000Z"9d010d50f8aa00051709e2a3e2b290e5"16618STANDARD110/e7281.14.09.03.CynataInitiates.pdf2018-11-04T23:51:45.000Z"bbdb6f3f7c28419e8383062452187c5f"146278STANDARD111/86ed3.14.09.09.Appendix3B-Exer.pdf2018-11-04T23:51:45.000Z"02c1fc710910d9d9a9ef37e7bc1f05ec"180362STANDARD111/conversions/86ed3.14.09.09.Appendix3B-Exer-thumb.jpg2018-11-05T09:21:48.000Z"65f92d1dbd0140710c415690ad69cd33"9746STANDARD112/4992b.14.09.09.Section708ANot.pdf2018-11-04T23:51:45.000Z"6cc4fab72dcdc55f2ee3dda5c8475a26"100393STANDARD112/conversions/4992b.14.09.09.Section708ANot-thumb.jpg2018-11-05T09:21:49.000Z"93cd34293f24c335b5e82f9c4c477dc8"13291STANDARD113/conversions/f0f5f.14.09.11.Appendix3B-Issu-thumb.jpg2018-11-05T09:21:50.000Z"4cc1bfefea8d16014d9b48f1b01f4e78"9989STANDARD113/f0f5f.14.09.11.Appendix3B-Issu.pdf2018-11-04T23:51:45.000Z"bd1055fd04749becd8e0578947db6915"181251STANDARD114/85c77.14.09.18.CynataAnnounces.pdf2018-11-04T23:51:46.000Z"25c4075eba5a0fdb08f85d3c803566f7"153245STANDARD114/conversions/85c77.14.09.18.CynataAnnounces-thumb.jpg2018-11-05T09:21:51.000Z"5a81b5381010e819ad4dbb9bc422be3e"19519STANDARD115/6bf17.14.09.26.Appendix3B-Exer.pdf2018-11-04T23:51:46.000Z"a777c6a42a4c6757c7af5b02bc1637ea"180452STANDARD115/conversions/6bf17.14.09.26.Appendix3B-Exer-thumb.jpg2018-11-05T09:21:52.000Z"824f8c9b1ed41d4bb180641400d4a72a"9791STANDARD116/0a29f.14.09.26.Section708ANot.pdf2018-11-04T23:51:46.000Z"d27b21d6849787519edb5c876982c21e"100399STANDARD116/conversions/0a29f.14.09.26.Section708ANot-thumb.jpg2018-11-05T09:21:52.000Z"e1c2f02ba1c1403bb6b332651fc5677f"13343STANDARD117/af25e.14.10.16.NoticeofAGM.pdf2018-11-04T23:51:46.000Z"12a44d604620073136a0f33dbfec719f"232141STANDARD117/conversions/af25e.14.10.16.NoticeofAGM-thumb.jpg2018-11-05T09:21:53.000Z"47979911a63e98486da46975965cd128"7218STANDARD118/63029.14.10.16.AnnualReportto.pdf2018-11-04T23:51:46.000Z"d867f98247d0a67ed34189559566372b"4595653STANDARD118/conversions/63029.14.10.16.AnnualReportto-thumb.jpg2018-11-05T09:21:55.000Z"45803e8403c15ff31b443e6d2bbcd14d"4953STANDARD119/41ac5.14.10.22.Appendix3B-Exer.pdf2018-11-04T23:51:48.000Z"028c76f4d192462a43572ee44d7610c1"180149STANDARD119/conversions/41ac5.14.10.22.Appendix3B-Exer-thumb.jpg2018-11-05T09:21:56.000Z"a61fdf3b35ccc91a62aa3be640bf7309"9785STANDARD12/1c389.13.08.01Appointmemntof.pdf2018-11-04T23:51:18.000Z"f0c1bba595663eda580212d04a0aac8c"217928STANDARD12/conversions/1c389.13.08.01Appointmemntof-thumb.jpg2018-11-06T05:47:21.000Z"9570e3d70d12f0254871d2bf86e0f25d"6650STANDARD120/conversions/e819c.14.10.22.Section708ANot-thumb.jpg2018-11-05T09:21:56.000Z"0e528205e276c8d134edb2039d45bfc0"13266STANDARD120/e819c.14.10.22.Section708ANot.pdf2018-11-04T23:51:48.000Z"ef6b4580767ac250f837b15e7e03242e"100068STANDARD121/8380d.14.10.23.CynatatoAppoin.pdf2018-11-04T23:51:48.000Z"c7facc6a36c635daa446f5d60afedfcf"152317STANDARD121/conversions/8380d.14.10.23.CynatatoAppoin-thumb.jpg2018-11-05T09:21:57.000Z"95ba992c642ce5fb7c227be48f6ac849"17126STANDARD122/conversions/f44e9.14.10.27.BBYInitiatesCy-thumb.jpg2018-11-05T09:21:58.000Z"2c83e077a9ca814ea73b2b04bf3edd43"5577STANDARD122/f44e9.14.10.27.BBYInitiatesCy.pdf2018-11-04T23:51:49.000Z"0d208c85c2e7d0d9f45eb9e396f4dce0"143996STANDARD123/a5aca.14.10.31.ActivitiesRepor.pdf2018-11-04T23:51:49.000Z"f4d58bf5bc0cd20f791743daa43f014b"215505STANDARD123/conversions/a5aca.14.10.31.ActivitiesRepor-thumb.jpg2018-11-05T09:21:59.000Z"b81ec448bcc05096a310cd5cc72c5076"18158STANDARD124/4e663.14.11.06.AustralianPaten.pdf2018-11-04T23:51:49.000Z"785db58b35ef4e25446cb7417c7e8b82"148974STANDARD124/conversions/4e663.14.11.06.AustralianPaten-thumb.jpg2018-11-05T09:22:00.000Z"4c56dd991ad020a0ea0c9eef96f368d7"15996STANDARD125/conversions/ffa82.14.11.07.RestrictedSecur-thumb.jpg2018-11-05T09:22:01.000Z"e75a1a25884fc2107b0dfb5fd07cddfe"13508STANDARD125/ffa82.14.11.07.RestrictedSecur.pdf2018-11-04T23:51:50.000Z"e8fd3417ae1746ee1c9f46779a020735"144941STANDARD126/7425e.14.11.12.Appendix3B-Exer.pdf2018-11-04T23:51:50.000Z"36403ba7f3b659cb792cac039ae3148b"180215STANDARD126/conversions/7425e.14.11.12.Appendix3B-Exer-thumb.jpg2018-11-05T09:22:01.000Z"988b4bec461d987894a60a85cc4391ef"9787STANDARD127/4ff9b.14.11.12.Section708ANot.pdf2018-11-04T23:51:50.000Z"988993103beeb71656250089de8b2baf"100272STANDARD127/conversions/4ff9b.14.11.12.Section708ANot-thumb.jpg2018-11-05T09:22:02.000Z"3c8092b7e267301115746cb6d56c498c"13322STANDARD128/0a872.14.11.14.Appendix3B-Exer.pdf2018-11-04T23:51:50.000Z"cc893eb440b53d0f4b7c5d25f724efd5"180366STANDARD128/conversions/0a872.14.11.14.Appendix3B-Exer-thumb.jpg2018-11-05T09:22:03.000Z"2a34739e52d66f8313e5efe52b38281a"9803STANDARD129/c749b.14.11.14.Section708ANot.pdf2018-11-04T23:51:50.000Z"c4e0744883f39e13c954c83b48497c51"101667STANDARD129/conversions/c749b.14.11.14.Section708ANot-thumb.jpg2018-11-05T09:22:04.000Z"ea6c09fda2798965479c9af523ed2ea3"13209STANDARD13/conversions/e855e.13.07.30Appendix4C-thumb.jpg2018-11-06T05:47:22.000Z"818075354f8b9af9a87d77d91f35752c"4951STANDARD13/e855e.13.07.30Appendix4C.pdf2018-11-04T23:51:18.000Z"7e54b9aa7df863ad543a0768c2b284c5"85407STANDARD130/5f0d6.14.11.18.CEOPresentation.pdf2018-11-04T23:51:51.000Z"2074bf38f3ccd67a6c199b7999a11826"1007001STANDARD130/conversions/5f0d6.14.11.18.CEOPresentation-thumb.jpg2018-11-05T09:22:05.000Z"7ab47071c28f5d0beba94bf003486de2"14231STANDARD131/beaa5.14.11.18.ResultsofAnnua.pdf2018-11-04T23:51:51.000Z"890b60025cac32654e5b4588bbc1f8f0"113358STANDARD131/conversions/beaa5.14.11.18.ResultsofAnnua-thumb.jpg2018-11-05T09:22:05.000Z"befb15830d58ba61f64e84ecf2d79011"5218STANDARD132/957ec.14.11.18.CynataBoardCha.pdf2018-11-04T23:51:52.000Z"dc92fce4f2c1a511c4bdc2ac6bb19d7c"144478STANDARD132/conversions/957ec.14.11.18.CynataBoardCha-thumb.jpg2018-11-05T09:22:06.000Z"90db2b2872cdf7cce9506267114b7681"12669STANDARD133/c3084.14.11.18.Appendix3Z-Howa.pdf2018-11-04T23:51:52.000Z"26f3981e9adef47c7dc88b94f08efe12"19437STANDARD133/conversions/c3084.14.11.18.Appendix3Z-Howa-thumb.jpg2018-11-05T09:22:07.000Z"2e94298d84f5ea5ee9187c24f895394d"10915STANDARD134/conversions/e16cf.14.11.18.Appendix3X-John-thumb.jpg2018-11-05T09:22:07.000Z"fdc1575b8224834021573a924a36bf05"9686STANDARD134/e16cf.14.11.18.Appendix3X-John.pdf2018-11-04T23:51:52.000Z"0d160ac4170d3766f343052c4dce0ae4"64770STANDARD135/c9436.14.11.24.Appendix3B-Rele.pdf2018-11-04T23:51:52.000Z"5fef14f2f670c1524cdce5b739e5fb30"180969STANDARD135/conversions/c9436.14.11.24.Appendix3B-Rele-thumb.jpg2018-11-05T09:22:09.000Z"0f462f8ee6988927650383b517851717"9588STANDARD136/5b830.14.11.25.CynataListedOp.pdf2018-11-04T23:51:52.000Z"40fb1cf54256c14d52a680aac9fb81bc"148572STANDARD136/conversions/5b830.14.11.25.CynataListedOp-thumb.jpg2018-11-05T09:22:10.000Z"faf9b26ce4a467f9cde0cc65f923da83"15724STANDARD137/0ff65.14.12.01.Notificationof.pdf2018-11-04T23:51:52.000Z"b332a946794241e980d5b6d7b8c5a1c6"197671STANDARD137/conversions/0ff65.14.12.01.Notificationof-thumb.jpg2018-11-05T09:22:12.000Z"b921e62eac4c3cec3883b7421b57b509"10979STANDARD138/755e7.14.12.04.CYPtoPresenta.pdf2018-11-04T23:51:53.000Z"748e40433aac56824d5126aaf1c60bc5"145451STANDARD138/conversions/755e7.14.12.04.CYPtoPresenta-thumb.jpg2018-11-05T09:22:12.000Z"971b662263168c8f61d0c4b3dee128b2"13002STANDARD139/c62c7.14.12.05.Appendix3B-Exer.pdf2018-11-04T23:51:53.000Z"68f4cc8d91c51c8d95c9be06609dad43"180580STANDARD139/conversions/c62c7.14.12.05.Appendix3B-Exer-thumb.jpg2018-11-05T09:22:13.000Z"b526c2bdb30430511ff279c721ad9b5d"9788STANDARD14/7e186.13.07.12.ECQtoAcquireS.pdf2018-11-04T23:51:18.000Z"027ab5bd5e351f60090f33d1672f901e"54580STANDARD14/conversions/7e186.13.07.12.ECQtoAcquireS-thumb.jpg2018-11-06T05:47:23.000Z"3ef3abe5300b7c17627158b812efa50f"18746STANDARD140/a1711.14.12.05.Section708ANot.pdf2018-11-04T23:51:53.000Z"ca32b89b4661449cf577c9b06b8ade2d"101090STANDARD140/conversions/a1711.14.12.05.Section708ANot-thumb.jpg2018-11-05T09:22:14.000Z"5632a8175443873f4aedcadf8e8b12f7"13182STANDARD141/52bc0.14.12.11.Appendix3B-Exer.pdf2018-11-04T23:51:54.000Z"5ea9eed93b6452ee6111c00b3e34fd51"180924STANDARD141/conversions/52bc0.14.12.11.Appendix3B-Exer-thumb.jpg2018-11-05T09:22:15.000Z"2fc8aef4d2fce3c294eb76019424869c"9788STANDARD142/c27c7.14.12.05.Section708ANot.pdf2018-11-04T23:51:54.000Z"edcb303e5da16e0e848b4f46e4376f4d"101689STANDARD142/conversions/c27c7.14.12.05.Section708ANot-thumb.jpg2018-11-05T09:22:16.000Z"354fbcd86fbbae832f8191f70e1ad15c"13188STANDARD143/ceed9.14.12.18.Appendix3B-Exer.pdf2018-11-04T23:51:54.000Z"34d3ff207ad7a513544a344e78a4e4cd"180843STANDARD143/conversions/ceed9.14.12.18.Appendix3B-Exer-thumb.jpg2018-11-05T09:22:17.000Z"71615191620623a4e12bb796b8009df5"9790STANDARD144/023e7.14.12.18.Section708ANot.pdf2018-11-04T23:51:54.000Z"7a025e41dbac881bd3a15a1f4954ef3a"101575STANDARD144/conversions/023e7.14.12.18.Section708ANot-thumb.jpg2018-11-05T09:22:17.000Z"e3bbc6fe89dbdd8764e689f6cb96cdb3"13152STANDARD145/conversions/ea259.14.12.18.Appendix3Y-Pe-thumb.jpg2018-11-05T09:22:18.000Z"ab8a4856dedd8af35716c0a2b501fd91"13321STANDARD145/ea259.14.12.18.Appendix3Y-Pe.pdf2018-11-04T23:51:54.000Z"584a14eef01fbf7f9e72bd1d71b76690"24966STANDARD146/a0a2f.14.12.24.Appendix3B-Exer.pdf2018-11-04T23:51:55.000Z"7fde20ca2344aa0e632e62291c3908ed"178234STANDARD146/conversions/a0a2f.14.12.24.Appendix3B-Exer-thumb.jpg2018-11-05T09:22:19.000Z"bbd10a9bf03b42bfc80d0e7ad775c80f"9661STANDARD147/3a581.14.12.18.Section708ANot.pdf2018-11-04T23:51:55.000Z"9d4eaabd98bfeace3ef67dcc4b468b41"101182STANDARD147/conversions/3a581.14.12.18.Section708ANot-thumb.jpg2018-11-05T09:22:20.000Z"6b3ac460a2c908179e1dfa358ab70284"13713STANDARD148/81f1f.14.12.31.Appendix3B-Exer.pdf2018-11-04T23:51:55.000Z"ba491cae93d3225d9d3e970f55690171"178262STANDARD148/conversions/81f1f.14.12.31.Appendix3B-Exer-thumb.jpg2018-11-05T09:22:20.000Z"d3f3894f3b39cdca70ea4e3dd18796d8"9679STANDARD149/conversions/facc5.14.12.31.Section708ANot-thumb.jpg2018-11-05T09:22:21.000Z"8805f7859854995e1957afa7a2c3e8e1"13667STANDARD149/facc5.14.12.31.Section708ANot.pdf2018-11-04T23:51:55.000Z"988fc39c8861aa045d59575066b6133a"101239STANDARD15/a7568.13.04.24.Appendix4C.pdf2018-11-04T23:51:18.000Z"523edfff37258c067b430e416f3d2921"84382STANDARD15/conversions/a7568.13.04.24.Appendix4C-thumb.jpg2018-11-06T05:47:23.000Z"4594441999ea133591e7d873fac2e5d2"10309STANDARD150/bbe7e.15.01.06.CompletionofEx.pdf2018-11-04T23:51:55.000Z"d317cdd42f5158afb282c471e73fce5a"445761STANDARD150/conversions/bbe7e.15.01.06.CompletionofEx-thumb.jpg2018-11-05T09:22:22.000Z"1a58064ceb27328e1a7938d11966a440"15330STANDARD151/80cdc.15.01.06.Section708ANot.pdf2018-11-04T23:51:56.000Z"75e714d32effda751a164aa5c9bff2b0"101423STANDARD151/conversions/80cdc.15.01.06.Section708ANot-thumb.jpg2018-11-05T09:22:23.000Z"80afef492eddf6a97dd2c3a721c0de62"13066STANDARD152/34fd2.15.01.14.Appendix3B.pdf2018-11-04T23:51:56.000Z"5c5caae1c6f92b38eca28b0e7e7c680a"180412STANDARD152/conversions/34fd2.15.01.14.Appendix3B-thumb.jpg2018-11-05T09:22:24.000Z"c107a5d2a2a8750486fbcfaf9432cfb6"9783STANDARD153/99811.15.01.14.Section708ANot.pdf2018-11-04T23:51:56.000Z"b92029b3f6ecf93591a534153a91f241"101030STANDARD153/conversions/99811.15.01.14.Section708ANot-thumb.jpg2018-11-05T09:22:24.000Z"c6ea6bc50b0e908d5ace4256b415c8ce"13767STANDARD154/8d944.15.01.15.Top20Sharehold.pdf2018-11-04T23:51:56.000Z"20bb6974bd395fb7767e01036d88336d"150185STANDARD154/conversions/8d944.15.01.15.Top20Sharehold-thumb.jpg2018-11-05T09:22:25.000Z"c929afead6e9458ad40a56331d646c9d"15631STANDARD155/conversions/f0ab5.15.01.30.ActivitiesRepor-thumb.jpg2018-11-05T09:22:26.000Z"61f2c41699ae30c5df0eb0dccda71b73"17611STANDARD155/f0ab5.15.01.30.ActivitiesRepor.pdf2018-11-04T23:51:56.000Z"c4a2c32f0000085410e47c1a9c06164b"216501STANDARD156/67b1b.15.02.03.CYPPartnerswit.pdf2018-11-04T23:51:57.000Z"03401c317ad2bfb16195a95f148e7a9e"195782STANDARD156/conversions/67b1b.15.02.03.CYPPartnerswit-thumb.jpg2018-11-05T09:22:27.000Z"a9e5c744ed8cb8573ef3c937d5f1af7f"18234STANDARD157/70f45.15.02.12.CynataEngagesL.pdf2018-11-04T23:51:57.000Z"b26fea8723bf1b2952f146eaa7a6dc42"164836STANDARD157/conversions/70f45.15.02.12.CynataEngagesL-thumb.jpg2018-11-05T09:22:28.000Z"5aec1f328e9489a0d8a050ba874759e8"18630STANDARD158/12bea.15.02.13.ChangeofShare.pdf2018-11-04T23:51:57.000Z"593a9657dce398963edaeb7ac0579ceb"146418STANDARD158/conversions/12bea.15.02.13.ChangeofShare-thumb.jpg2018-11-05T09:22:29.000Z"2c529d7cddbb91bd95e6516b980c8dc4"12822STANDARD159/49a18.15.02.16.CYPEngagesCont.pdf2018-11-04T23:51:57.000Z"c0e7142503bc603df2b5b88d3613edf7"158766STANDARD159/conversions/49a18.15.02.16.CYPEngagesCont-thumb.jpg2018-11-05T09:22:29.000Z"b29210926531e9084bd770edd881e829"16173STANDARD16/cb753.13.04.11.CynataIncorpora.pdf2018-11-04T23:51:18.000Z"13bbb72f08a1af4c8611d81c6660ac28"154855STANDARD16/conversions/cb753.13.04.11.CynataIncorpora-thumb.jpg2018-11-06T05:47:24.000Z"5a2d0d791588143b0c64d80f18104186"18037STANDARD160/14d12.15.02.17.TradingHalt.pdf2018-11-04T23:51:57.000Z"d809574245ce482f28f6c894bcedf977"197620STANDARD160/conversions/14d12.15.02.17.TradingHalt-thumb.jpg2018-11-05T09:22:31.000Z"79a2b3ad890d41a6430eaacaec02e54b"5546STANDARD161/89fd7.15.02.19.CynataAchieves.pdf2018-11-04T23:51:58.000Z"1c7746e8514213a9b4bb9124c07643da"170916STANDARD161/conversions/89fd7.15.02.19.CynataAchieves-thumb.jpg2018-11-05T09:22:32.000Z"657962c9b6ada75f8514c93b75355f06"17873STANDARD162/37c94.15.02.20.BBYUpdatesCyna.pdf2018-11-04T23:51:58.000Z"40e2e2b080441802a9472dd146c2d35b"147276STANDARD162/conversions/37c94.15.02.20.BBYUpdatesCyna-thumb.jpg2018-11-05T09:22:33.000Z"90a25aafb1c980c4f4a741aa0677b77a"15756STANDARD163/conversions/e63a8.15.02.23.InvestorPresent-thumb.jpg2018-11-05T09:22:34.000Z"3aa1a7664931abbbbe87d5a0ddb6d19f"13991STANDARD163/e63a8.15.02.23.InvestorPresent.pdf2018-11-04T23:51:58.000Z"d6cb30de538aaa91b2b47fa65ea90c3e"1123069STANDARD164/conversions/e08ad.15.02.26.Appendix4DHalf--thumb.jpg2018-11-05T09:22:35.000Z"47b9651448f2365b921038506478d7b4"15008STANDARD164/e08ad.15.02.26.Appendix4DHalf-.pdf2018-11-04T23:51:58.000Z"3a6e4f77e4b460c86d30b53205f36591"1989504STANDARD165/b4b1e.15.03.05.CynataPresentin.pdf2018-11-04T23:51:59.000Z"4622f7f159f0f78269ad6196c58b3da5"152468STANDARD165/conversions/b4b1e.15.03.05.CynataPresentin-thumb.jpg2018-11-05T09:22:36.000Z"fbe93f01556c075b5b3461028a21010b"15681STANDARD166/b09df.15.03.06.VestingConditio.pdf2018-11-04T23:52:00.000Z"c54751ff0583747e16670e91d3d085f7"148994STANDARD166/conversions/b09df.15.03.06.VestingConditio-thumb.jpg2018-11-05T09:22:37.000Z"eb943c5ff819ab12632aceddc36b11ba"14493STANDARD167/conversions/f897a.15.03.12.CommencesFurthe-thumb.jpg2018-11-05T09:22:38.000Z"8c355c0bf8702d913372d248c628bb1c"17276STANDARD167/f897a.15.03.12.CommencesFurthe.pdf2018-11-04T23:52:00.000Z"ba35ced8cd6fc08fc88e443eea6d8ffa"150932STANDARD168/conversions/f3a8c.15.03.16.ExecDirectorco-thumb.jpg2018-11-05T09:22:39.000Z"dce4dc10a2b2faeb03630d879a246612"14303STANDARD168/f3a8c.15.03.16.ExecDirectorco.pdf2018-11-04T23:52:00.000Z"1d946b73bd641f9d754a8835490e6643"173311STANDARD169/c9e11.15.03.16.Appendix3Y-Stew.pdf2018-11-04T23:52:00.000Z"dcbe36c0d9cbd5ef03972c36a90984bd"25808STANDARD169/conversions/c9e11.15.03.16.Appendix3Y-Stew-thumb.jpg2018-11-05T09:22:40.000Z"73500bbacfb13d3bbad92469d5a8fb31"13877STANDARD17/76a15.13.02.26SettlementofAc.pdf2018-11-04T23:51:19.000Z"ceba5db56e17d7aa31dba1c5a440acc4"46954STANDARD17/conversions/76a15.13.02.26SettlementofAc-thumb.jpg2018-11-06T05:47:25.000Z"1904485c530e06c636be83f895df43a6"11602STANDARD170/928a7.15.03.18.CynataCEOtoCh.pdf2018-11-04T23:52:00.000Z"4d0480d14b732caf64d1e11bfc4c2c77"154367STANDARD170/conversions/928a7.15.03.18.CynataCEOtoCh-thumb.jpg2018-11-05T09:22:40.000Z"22b59d9891f2533047736808ede0a42c"17488STANDARD171/5dba8.15.03.30.Appendix3Y-John.pdf2018-11-04T23:52:00.000Z"7ca995949ffcb8ca55153342b6237ea3"23698STANDARD171/conversions/5dba8.15.03.30.Appendix3Y-John-thumb.jpg2018-11-05T09:22:41.000Z"5c60702449ae22c8c8691e3bc16fba85"12323STANDARD172/75859.15.04.30.ActivitiesRepor.pdf2018-11-04T23:52:00.000Z"c63428a08ee10c8f52a3a32bb0100017"216942STANDARD172/conversions/75859.15.04.30.ActivitiesRepor-thumb.jpg2018-11-05T09:22:42.000Z"d2f196229116e6a513c4f3b4f927659b"18771STANDARD173/8c20b.15.05.08.ResponsetoASX.pdf2018-11-04T23:52:00.000Z"096c6efb94be9d854e3a868fcab59d37"101361STANDARD173/conversions/8c20b.15.05.08.ResponsetoASX-thumb.jpg2018-11-05T09:22:43.000Z"7b162eb9d78cb0815081e4757b2eeac6"5268STANDARD174/3607c.15.05.21.Cynata-CymerusP.pdf2018-11-04T23:52:01.000Z"25d165aa0e206db4c109064b89be4b43"179985STANDARD174/conversions/3607c.15.05.21.Cynata-CymerusP-thumb.jpg2018-11-05T09:22:44.000Z"c4fb192a184ef8b3f07a1eeb1abed0cd"19377STANDARD175/4a545.15.05.25.RDTaxIncentiv.pdf2018-11-04T23:52:01.000Z"1731914b768ec18b9612049780b9c9a4"145684STANDARD175/conversions/4a545.15.05.25.RDTaxIncentiv-thumb.jpg2018-11-05T09:22:45.000Z"532c3887f7853c9773eddce0478e8e7c"11862STANDARD176/conversions/e800b.15.07.15.CynataCompletes-thumb.jpg2018-11-05T09:22:45.000Z"8eaab3bfd176fa172618754bf951da69"19915STANDARD176/e800b.15.07.15.CynataCompletes.pdf2018-11-04T23:52:01.000Z"a999325cb365413d881feb7c4f276c66"163783STANDARD177/842ab.15.07.15.Section708ANot.pdf2018-11-04T23:52:01.000Z"3667a3fbe1d2b10244231844775a2991"107542STANDARD177/conversions/842ab.15.07.15.Section708ANot-thumb.jpg2018-11-05T09:22:46.000Z"376125c5710c723d0efd24fa8f038aaa"12809STANDARD178/7317c.15.07.17.Appendix3B.pdf2018-11-04T23:52:01.000Z"9097d81b69b11fec513144515a683900"186820STANDARD178/conversions/7317c.15.07.17.Appendix3B-thumb.jpg2018-11-05T09:22:47.000Z"0262002e146846aa98b7b05072281e4a"10792STANDARD179/354fb.15.07.17.InformationRequ.pdf2018-11-04T23:52:01.000Z"1aef7b2d270704dc21b3b077922e6bc1"105678STANDARD179/conversions/354fb.15.07.17.InformationRequ-thumb.jpg2018-11-05T09:22:48.000Z"2b9ce3e7e64fb3cb37683d5e7c116d30"14541STANDARD18/ae091.13.02.26Appendix4DHa.pdf2018-11-04T23:51:19.000Z"d0086267127461feebcec369096a1d67"2461335STANDARD18/conversions/ae091.13.02.26Appendix4DHa-thumb.jpg2018-11-06T05:47:26.000Z"ab8dadc9385877b6d733133a8636b4d2"11035STANDARD180/83e12.15.07.30.CynatainHeart.pdf2018-11-04T23:52:01.000Z"8c17ebc1db7e8012eb002b49aba3df5e"181714STANDARD180/conversions/83e12.15.07.30.CynatainHeart-thumb.jpg2018-11-05T09:22:49.000Z"a2a740b7ed7bcafaab5d5a1ddd505c89"20548STANDARD181/7b4d6.15.07.30.ActivitiesRepor.pdf2018-11-04T23:52:02.000Z"dc10517c605570a18ae6c71c0bb766e6"193360STANDARD181/conversions/7b4d6.15.07.30.ActivitiesRepor-thumb.jpg2018-11-05T09:22:50.000Z"a00e0b383ec8e7d3fbfeced814fd639d"19106STANDARD182/7f742.15.08.21.Appendix4EFi.pdf2018-11-04T23:52:02.000Z"babbcb0cbb1315172b48c8a189e500a2"871940STANDARD182/conversions/7f742.15.08.21.Appendix4EFi-thumb.jpg2018-11-05T09:22:51.000Z"6d79f60f95cc20086e8d655994e4722a"14082STANDARD183/070e1.15.08.21.Appendix4G.pdf2018-11-04T23:52:03.000Z"813925a1e3e3bb64e6a1a6514683a6e3"99269STANDARD183/conversions/070e1.15.08.21.Appendix4G-thumb.jpg2018-11-05T09:22:51.000Z"918f74fee5431aa532a583ef64a1728b"13624STANDARD184/63faa.15.09.03.SeeThruEquityIn.pdf2018-11-04T23:52:03.000Z"319e202d303b332ac3d4306efc42c560"150877STANDARD184/conversions/63faa.15.09.03.SeeThruEquityIn-thumb.jpg2018-11-05T09:22:52.000Z"f3091e6675cc7537f3f179578d3170f7"5249STANDARD185/319d2.15.09.07.CynatatoPresen.pdf2018-11-04T23:52:03.000Z"47a90b693a447896a984ddd404b26e47"155669STANDARD185/conversions/319d2.15.09.07.CynatatoPresen-thumb.jpg2018-11-05T09:22:53.000Z"960ba52e0d3f3eb5376fffc0e63cf10c"15952STANDARD186/9adfe.15.10.06.NoticeofAGM.pdf2018-11-04T23:52:04.000Z"39e57b9f4c88229f7f99c6133288dfd6"618147STANDARD186/conversions/9adfe.15.10.06.NoticeofAGM-thumb.jpg2018-11-05T09:22:54.000Z"3b120c44ff0615b71f58da75dc291ce1"8034STANDARD187/conversions/d026f.15.10.06.AnnualReportto-thumb.jpg2018-11-05T09:22:55.000Z"afa7a20841701352429628a7e1a4d8be"4951STANDARD187/d026f.15.10.06.AnnualReportto.pdf2018-11-04T23:52:04.000Z"50feffbece0becc7067adc19b7f1972f"905335STANDARD188/6f6f9.15.10.14.CYPinMajorNew.pdf2018-11-04T23:52:04.000Z"edebff59c5d4e63c3d7ce962ea137786"166560STANDARD188/conversions/6f6f9.15.10.14.CYPinMajorNew-thumb.jpg2018-11-05T09:22:56.000Z"aac00fea4fcbd221ea9b02230852966b"19086STANDARD189/8a314.15.10.29.ActivitiesRepor.pdf2018-11-04T23:52:05.000Z"b89d6ddd6d229c27b2dd133a3f9d7a8e"273829STANDARD189/conversions/8a314.15.10.29.ActivitiesRepor-thumb.jpg2018-11-05T09:22:56.000Z"624ba9ddce2a544bdd8ef16d0ce28bec"18429STANDARD19/355ab.13.02.06ECQReportsImpo.pdf2018-11-04T23:51:21.000Z"65cfe1d049b51417818d01d423b6d181"263978STANDARD19/conversions/355ab.13.02.06ECQReportsImpo-thumb.jpg2018-11-06T05:47:27.000Z"8aae502e72debf638d62b80710a7593a"5719STANDARD190/6ac76.15.11.05.CynataEngagesC.pdf2018-11-04T23:52:05.000Z"4bc59b9ad36d4f7b386dbb85d7ae9d4e"183741STANDARD190/conversions/6ac76.15.11.05.CynataEngagesC-thumb.jpg2018-11-05T09:22:57.000Z"11d0ba90d188b8f2b88fe83fb1d147ab"18679STANDARD191/conversions/db2a4.15.11.06.RestrictedSecur-thumb.jpg2018-11-05T09:22:58.000Z"6c8073d82b8a00f46b69760b45a0b7d5"13720STANDARD191/db2a4.15.11.06.RestrictedSecur.pdf2018-11-04T23:52:05.000Z"1b6341c028fe008eae1523a21eab7b28"151622STANDARD192/a6f10.15.11.11.MDsAGMPresent.pdf2018-11-04T23:52:05.000Z"fb6ffba169048fc8f9b5e60a86890d8b"1057975STANDARD192/conversions/a6f10.15.11.11.MDsAGMPresent-thumb.jpg2018-11-05T09:22:59.000Z"d5e22453bd018c257655796f1e0a6ab0"14191STANDARD193/81887.15.11.11.ResultsofAnnua.pdf2018-11-04T23:52:06.000Z"2f7f1427d9534d8680fbe9c7a363580c"109593STANDARD193/conversions/81887.15.11.11.ResultsofAnnua-thumb.jpg2018-11-05T09:23:00.000Z"e6b9a067aa34e179914af5400e5b0fed"13812STANDARD194/conversions/eae4b.15.11.30.ExpiryofUnlist-thumb.jpg2018-11-05T09:23:01.000Z"a613f2ffd76828f8a1bd5f0feb13a138"12848STANDARD194/eae4b.15.11.30.ExpiryofUnlist.pdf2018-11-04T23:52:06.000Z"2a878f2386509ae69fb36d8c11d1eb86"152059STANDARD195/50a5b.15.12.03.CYPEntersLette.pdf2018-11-04T23:52:06.000Z"e0977f62f5acc5185084f6fe7b37816b"168686STANDARD195/conversions/50a5b.15.12.03.CYPEntersLette-thumb.jpg2018-11-05T09:23:01.000Z"6fadbf858d8214d6e9628db06829bf47"15291STANDARD196/a176c.15.12.08.Rodman_Renshaw.pdf2018-11-04T23:52:06.000Z"a1e060b9bbbeff412ca19f9bf3ec9ff8"151845STANDARD196/conversions/a176c.15.12.08.Rodman_Renshaw-thumb.jpg2018-11-05T09:23:02.000Z"afca1328785d1e71b3b6f6b58303517e"12522STANDARD197/87f59.15.12.16.Appendix3B.pdf2018-11-04T23:52:06.000Z"e67d8fd9e6c1ac1fe7e759c81f2aeb09"185532STANDARD197/conversions/87f59.15.12.16.Appendix3B-thumb.jpg2018-11-05T09:23:03.000Z"6867072a9dbc0316e2db9f54574f3275"12348STANDARD198/conversions/d608b.15.12.17.CynataEntersLe-thumb.jpg2018-11-05T09:23:04.000Z"796cdd58e1369ebcbe2a5b8c45b44108"19148STANDARD198/d608b.15.12.17.CynataEntersLe.pdf2018-11-04T23:52:07.000Z"9ea40fd0d6b27ba2569c1fa89b57afb5"169877STANDARD199/conversions/d8374.16.01.12.CynataCLIStudy-thumb.jpg2018-11-05T09:23:05.000Z"25a97bbdd71966d509a08cf85ced02fc"9397STANDARD199/d8374.16.01.12.CynataCLIStudy.pdf2018-11-04T23:52:07.000Z"5510e8d96debd682403bcc30698323a8"280179STANDARD2/3a2d5.Cynata_30May14a.pdf2018-11-04T10:54:50.000Z"ae4232af4d7fef4be98041b0caa72a47"444197STANDARD2/conversions/3a2d5.Cynata_30May14a-thumb.jpg2018-11-06T05:47:13.000Z"52357ada8a840d1076f6d6c82ba0034b"18768STANDARD20/conversions/d98b9.13.02.05ExtensiontoDD-thumb.jpg2018-11-06T05:47:27.000Z"8fe5cbede9a038bac92a4d03437cae49"15474STANDARD20/d98b9.13.02.05ExtensiontoDD.pdf2018-11-04T23:51:21.000Z"e94dcc0833a2e98ed624195f65798451"47584STANDARD200/conversions/e48a6.16.01.28.CynataReceives-thumb.jpg2018-11-05T09:23:06.000Z"f28ff4c22b7e57594a0da6e6c1fa53c3"18539STANDARD200/e48a6.16.01.28.CynataReceives.pdf2018-11-04T23:52:07.000Z"6c5a3832f03f6b8fdf02a3d02068a8be"191198STANDARD201/6c3ef.16.01.29.ActivitiesRepor.pdf2018-11-04T23:52:07.000Z"a7cdcac13dfe4a73c54eb30a2c0c9b86"262346STANDARD201/conversions/6c3ef.16.01.29.ActivitiesRepor-thumb.jpg2018-11-05T09:23:07.000Z"3dd8f7cfdd63a1a191483dc5aeb05cf6"17814STANDARD202/bf8db.16.02.16.CynataReceives.pdf2018-11-04T23:52:08.000Z"ec18bfde5317e1e706ba560ac6d312fc"248647STANDARD202/conversions/bf8db.16.02.16.CynataReceives-thumb.jpg2018-11-05T09:23:08.000Z"702db1884eab5120e5de317729507b91"9581STANDARD203/conversions/d8893.16.02.22.Appendix3B-thumb.jpg2018-11-05T09:23:09.000Z"d1c5a118cff0da9c7187c7cefd41ac5f"9816STANDARD203/d8893.16.02.22.Appendix3B.pdf2018-11-04T23:52:08.000Z"37736ebb3119f809a0aa7f7456fc0456"183662STANDARD204/16.02.26.Appendix4DHa.pdf2018-11-04T23:52:08.000Z"da6b48b91efb7476f62095942dc3bf53"1781168STANDARD204/conversions/16.02.26.Appendix4DHa-thumb.jpg2018-11-05T09:23:10.000Z"d26d732468964b9857ded839f18a4e70"15009STANDARD205/4a357.16.03.03.CynataEntersAg.pdf2018-11-04T23:52:09.000Z"d9037a7813067a5282af7648691d0719"269498STANDARD205/conversions/4a357.16.03.03.CynataEntersAg-thumb.jpg2018-11-05T09:23:11.000Z"27ff5c359ab9deddb622e18e8020354c"8443STANDARD206/16.04.07.Compelling-Results-from-Pre-Clinical-Stem-Cell-Study-in-GvHD-1.pdf2018-11-04T23:52:09.000Z"8c5d577a3394d5e7d03ed3717f4c5d27"197444STANDARD206/conversions/16.04.07.Compelling-Results-from-Pre-Clinical-Stem-Cell-Study-in-GvHD-1-thumb.jpg2018-11-05T09:23:12.000Z"0f20f0cab2c428e3aebff9ae89a1c4ae"16823STANDARD207/16.04.29.Activities-Report-Appendix-4C.pdf2018-11-04T23:52:10.000Z"6ff3345173ecb326031307519f915d65"364747STANDARD207/conversions/16.04.29.Activities-Report-Appendix-4C-thumb.jpg2018-11-05T09:23:14.000Z"fc3ad1f15a00a1d521694238ea178bff"8830STANDARD208/16.04.29.Cynata-Regience-Extend-Entitlement-Period.pdf2018-11-04T23:52:10.000Z"b38938bba247ad09172d2a047aa88ba0"176871STANDARD208/conversions/16.04.29.Cynata-Regience-Extend-Entitlement-Period-thumb.jpg2018-11-05T09:23:15.000Z"5ee6544fb3bbd40c236e4e3794f80e62"16950STANDARD209/16.05.02.Decision-to-Grant-Patent-for-Cymerus-MSC-Technology-in-Japan-2.pdf2018-11-04T23:52:11.000Z"c0da7d754f8d16bc2193de895f15add8"163864STANDARD209/conversions/16.05.02.Decision-to-Grant-Patent-for-Cymerus-MSC-Technology-in-Japan-2-thumb.jpg2018-11-05T09:23:16.000Z"d05a1d5d1349d8b2a66f12cf2b7a622e"17935STANDARD21/conversions/fe367.13.01.29Appendix4C-thumb.jpg2018-11-06T05:47:28.000Z"a197acf904f7e7e0165aaf80507efaf5"10318STANDARD21/fe367.13.01.29Appendix4C.pdf2018-11-04T23:51:21.000Z"3cc8d2ca504ea808b9edb945d200d39a"84584STANDARD210/16.05.05.CYP-Manufactures-CT-Product-Files-Further-Patent-Application.pdf2018-11-04T23:52:12.000Z"d64d2cbfbd0098888eb55ee719eb1200"171652STANDARD210/conversions/16.05.05.CYP-Manufactures-CT-Product-Files-Further-Patent-Application-thumb.jpg2018-11-05T09:23:17.000Z"64e06d04f3099e1be5803dbac4523f8d"17269STANDARD211/16.05.09.Cynata-Enters-Agreement-with-apceth-GmbH-Co-KG.pdf2018-11-04T23:52:12.000Z"e839fd2e318ac9a731e80b2d16b60bd0"175823STANDARD211/conversions/16.05.09.Cynata-Enters-Agreement-with-apceth-GmbH-Co-KG-thumb.jpg2018-11-05T09:23:18.000Z"84674bd182ab790699c3105f2e5f79ff"17887STANDARD212/16.06.09.Cynata-Appoints-Paul-K-Wotton-PhD-to-Board-of-Directors.pdf2018-11-04T23:52:12.000Z"57fd316d5d078e7699dde6f754e16a4e"177336STANDARD212/conversions/16.06.09.Cynata-Appoints-Paul-K-Wotton-PhD-to-Board-of-Directors-thumb.jpg2018-11-05T09:23:19.000Z"67376a32928512aa30b53a318a34b1d3"16841STANDARD213/16.06.09.Appendix-3X-Paul-Wotton.pdf2018-11-04T23:52:13.000Z"d4ea657f1e2a52d52a6ea10d8448807a"64176STANDARD213/conversions/16.06.09.Appendix-3X-Paul-Wotton-thumb.jpg2018-11-05T09:23:19.000Z"7954c31d20c1adea559e642d6f11ee8f"9690STANDARD214/16.06.21.Cynata-Prepares-for-Phase-1-Clinical-Trial.pdf2018-11-04T23:52:13.000Z"db508892b2a70796df61a5bb35929afd"184346STANDARD214/conversions/16.06.21.Cynata-Prepares-for-Phase-1-Clinical-Trial-thumb.jpg2018-11-05T09:23:20.000Z"119b2560b727bc701734efef00a3e1db"15942STANDARD215/16.06.30.Cynata-Receives-Investment-Offer-from-Regience.pdf2018-11-04T23:52:13.000Z"0cedc754fc93e3ae77dc639e8f244ad5"172711STANDARD215/conversions/16.06.30.Cynata-Receives-Investment-Offer-from-Regience-thumb.jpg2018-11-05T09:23:21.000Z"2077b8a089cf64d934f34460a7ed00c2"15743STANDARD216/16.07.29.Activities-Report-Appendix-4C.pdf2018-11-04T23:52:14.000Z"442ac154ca21550d98a19e9cf929b276"781720STANDARD216/conversions/16.07.29.Activities-Report-Appendix-4C-thumb.jpg2018-11-05T09:23:22.000Z"9fd898c679795fc8f19ac92d1834368b"18318STANDARD217/16.08.01.Cynata-Files-Application-to-Commence-Phase-1-Clinical-Trial.pdf2018-11-04T23:52:14.000Z"bcf58486ae9f7743f3ad672514c63621"162985STANDARD217/conversions/16.08.01.Cynata-Files-Application-to-Commence-Phase-1-Clinical-Trial-thumb.jpg2018-11-05T09:23:23.000Z"f71a660de172971d50faa9d20c79462c"5505STANDARD218/16.08.17.Expiry-of-Unlisted-Options.pdf2018-11-04T23:52:14.000Z"22cecf61084d65fc40f69e183e732344"164463STANDARD218/conversions/16.08.17.Expiry-of-Unlisted-Options-thumb.jpg2018-11-05T09:23:24.000Z"0247c96180f902742479d651e968656d"12295STANDARD219/16.08.19.Appendix-4E-Financial-Statements.pdf2018-11-04T23:52:14.000Z"ae12da57955f524ee5ad6426b6ac317b"936987STANDARD219/conversions/16.08.19.Appendix-4E-Financial-Statements-thumb.jpg2018-11-05T09:23:25.000Z"d8e35638066ad1fdc5f64a0b7897b7b0"14057STANDARD22/ce375.13.09.20.TradingHalt.pdf2018-11-04T23:51:21.000Z"776ba0e15b12ac4c29949f4de5f73fdb"114007STANDARD22/conversions/ce375.13.09.20.TradingHalt-thumb.jpg2018-11-06T05:47:29.000Z"c663e7ca8054def5a01261e4576b0a91"6855STANDARD220/16.08.19.Appendix-4G-signed.pdf2018-11-04T23:52:15.000Z"c2ef46bf822992476c3df386ed620779"127448STANDARD220/conversions/16.08.19.Appendix-4G-signed-thumb.jpg2018-11-05T09:23:25.000Z"8247c6adac3fbbffe7fb445754e678de"3500STANDARD221/16.09.02.Trading-Halt-Request-v2.pdf2018-11-04T23:52:15.000Z"0202431c0640f88d3c963ce80d5338cc"475794STANDARD221/conversions/16.09.02.Trading-Halt-Request-v2-thumb.jpg2018-11-05T09:23:26.000Z"51574c271ea832cb0675b62f85d870cb"9717STANDARD222/16.09.05.Cynata-Signs-Non-Binding-Terms-Sheet-with-Fujifilm.pdf2018-11-04T23:52:15.000Z"adca1e5e9c224f09b32f2640c4c8f772"170701STANDARD222/conversions/16.09.05.Cynata-Signs-Non-Binding-Terms-Sheet-with-Fujifilm-thumb.jpg2018-11-05T09:23:27.000Z"7b34042afe7aff1212cf420b7a690ea0"15730STANDARD223/16.09.05.Cynata-Determines-not-to-proceed-with-Regience-Investment-Offer.pdf2018-11-04T23:52:15.000Z"b6759ead1b9495332fd10116fb52bb1e"201504STANDARD223/conversions/16.09.05.Cynata-Determines-not-to-proceed-with-Regience-Investment-Offer-thumb.jpg2018-11-05T09:23:28.000Z"2a7ac5c418773fa3d4aab3c21bc783ae"15682STANDARD224/16.09.07.Corporate-Presentation.pdf2018-11-04T23:52:16.000Z"ed8e42b99849d86970f3e44b5e1d63fa"1461863STANDARD224/conversions/16.09.07.Corporate-Presentation-thumb.jpg2018-11-05T09:23:29.000Z"89194de574db131fca2851fcf7ee9157"17018STANDARD225/16.09.09.Appendix-3Y-Stewart-Washer.pdf2018-11-04T23:52:16.000Z"d1329e16ea297d8a9bc7aa6d2c98bd05"25030STANDARD225/conversions/16.09.09.Appendix-3Y-Stewart-Washer-thumb.jpg2018-11-05T09:23:30.000Z"ed99cda3800cdc1c3c17a6ddef1c2c44"13895STANDARD226/16.09.12.Expiry-of-Unlisted-Options.pdf2018-11-04T23:52:16.000Z"e5e50dc2f92df0b44e7a1de2e8077eed"164093STANDARD226/conversions/16.09.12.Expiry-of-Unlisted-Options-thumb.jpg2018-11-05T09:23:31.000Z"6b59024ef783f8af069f70d27947b6b7"12592STANDARD227/16.09.19.UK-Regulatory-Authority-Approves-GvHD-Clinical-Trial.pdf2018-11-04T23:52:17.000Z"00d439adb03c607a0cfc507df77fa853"223052STANDARD227/conversions/16.09.19.UK-Regulatory-Authority-Approves-GvHD-Clinical-Trial-thumb.jpg2018-11-05T09:23:32.000Z"8ffc79d6cc241189d5e5b20515c8610d"17890STANDARD228/16.10.13.Notice-of-AGM-Proxy-Form.pdf2018-11-04T23:52:17.000Z"35be894ba5c5f48219b40f5472ecc737"1138833STANDARD228/conversions/16.10.13.Notice-of-AGM-Proxy-Form-thumb.jpg2018-11-05T09:23:33.000Z"519cb528d6dff587b3eab31fd33a83f4"8063STANDARD229/16.10.13.Annual-Report-to-Shareholders.pdf2018-11-04T23:52:18.000Z"e732cb46e816c18ad758f37c0ae485e2"865975STANDARD229/conversions/16.10.13.Annual-Report-to-Shareholders-thumb.jpg2018-11-05T09:23:33.000Z"d015187d95f3afdceb649d75bb7bd3a4"4975STANDARD23/131b9.13.09.20.RequestforTrad.pdf2018-11-04T23:51:21.000Z"2951db8233cef175bb37da0b8222140e"84565STANDARD23/conversions/131b9.13.09.20.RequestforTrad-thumb.jpg2018-11-06T05:47:29.000Z"7165a3b5fd435eaa1da29c38bf1b8f06"5210STANDARD230/16.10.17.Efficacy-for-CYP-MSC-Technology-in-Preclinical-Asthma-Study.pdf2018-11-04T23:52:18.000Z"505a7d43a88660f72a21b80b1c20e088"204872STANDARD230/conversions/16.10.17.Efficacy-for-CYP-MSC-Technology-in-Preclinical-Asthma-Study-thumb.jpg2018-11-05T09:23:34.000Z"189d6f9f0b3bc2b8c95637dd299b2d86"18801STANDARD231/16.10.31.Activities-Report-Appendix-4C.pdf2018-11-04T23:52:18.000Z"6a8a97f7957ad01600e32fe0773033f7"238874STANDARD231/conversions/16.10.31.Activities-Report-Appendix-4C-thumb.jpg2018-11-05T09:23:35.000Z"1fe8543ad2daa6ffb4f88a46c559194c"18682STANDARD232/16.11.15.Cynata-Receives-1.749m-RD-Tax-Incentive-Refund.pdf2018-11-04T23:52:18.000Z"d0c45cd2b906742cc5615572770a75cc"165854STANDARD232/conversions/16.11.15.Cynata-Receives-1.749m-RD-Tax-Incentive-Refund-thumb.jpg2018-11-05T09:23:36.000Z"5a5ade99bc75d71f881943438a8b2f46"13198STANDARD233/16.11.16.AGM-Presentation.pdf2018-11-04T23:52:19.000Z"0896de728202be36aac8b47a98575406"756456STANDARD233/conversions/16.11.16.AGM-Presentation-thumb.jpg2018-11-05T09:23:37.000Z"287380ae63f462daa3e41cf9a6606bae"17511STANDARD234/16.11.16.Results-of-AGM.pdf2018-11-04T23:52:19.000Z"01cf78d9d95451760c5b8fa066f16a55"520110STANDARD234/conversions/16.11.16.Results-of-AGM-thumb.jpg2018-11-05T09:23:38.000Z"073e9ba609d7b67a0bd2a6825b523be4"9068STANDARD235/16.11.17.Appendix-3B.pdf2018-11-04T23:52:19.000Z"e1a119b69e37e20491dfff2f2e8f669c"189290STANDARD235/conversions/16.11.17.Appendix-3B-thumb.jpg2018-11-05T09:23:39.000Z"b8256d2d91d84ef833e711230a3abd9a"9850STANDARD236/16.11.17.Appendix-3Y-x-4-1.pdf2018-11-04T23:52:19.000Z"4f9766386560dacd32f278cf004428c9"73562STANDARD236/conversions/16.11.17.Appendix-3Y-x-4-1-thumb.jpg2018-11-05T09:23:40.000Z"51f43a3cef5946475267afa750c65097"12908STANDARD237/16.11.29.Cynata-Files-Further-Patent-Application.pdf2018-11-04T23:52:20.000Z"6efaf1c0dcc186611da780a8e2e21c6d"162306STANDARD237/conversions/16.11.29.Cynata-Files-Further-Patent-Application-thumb.jpg2018-11-05T09:23:40.000Z"78ef9d4ed1121044825e221ee605fff7"16565STANDARD238/16.12.09.Change-of-Share-Registry-Address.pdf2018-11-04T23:52:20.000Z"a953e88be5b02faefa1585516d1ae60c"215701STANDARD238/conversions/16.12.09.Change-of-Share-Registry-Address-thumb.jpg2018-11-05T09:23:41.000Z"36d1939d37f015eacfa3ee63847db188"9676STANDARD239/16.12.13.Cynata-Receives-NHS-HRA-Approval-for-Clinical-Study.pdf2018-11-04T23:52:20.000Z"273483de4bb18ddcb67bf8ab95925db4"201384STANDARD239/conversions/16.12.13.Cynata-Receives-NHS-HRA-Approval-for-Clinical-Study-thumb.jpg2018-11-05T09:23:42.000Z"55f0d0f53e35feeae82bb0d6a743610d"17801STANDARD24/00cea.13.09.18.CEOPresentation.pdf2018-11-04T23:51:21.000Z"0818d11c656f14295d7c88ee0b50e2e9"1108595STANDARD24/conversions/00cea.13.09.18.CEOPresentation-thumb.jpg2018-11-06T05:47:30.000Z"7e001a21c8980a3ae3e4487698b1fdde"13561STANDARD240/16.12.15.Cynatas-Clinical-Study-Approved-in-Australia.pdf2018-11-04T23:52:20.000Z"c6ac86a830185b15cdab9b400b25074e"201282STANDARD240/conversions/16.12.15.Cynatas-Clinical-Study-Approved-in-Australia-thumb.jpg2018-11-05T09:23:43.000Z"737c76f4384ae882011f65042350f340"16612STANDARD241/16.12.29.Proposed-Fujifilm-Development-Commericialisation-Transaction.pdf2018-11-04T23:52:20.000Z"3df798413773a067e9924bb154a7ff51"164525STANDARD241/conversions/16.12.29.Proposed-Fujifilm-Development-Commericialisation-Transaction-thumb.jpg2018-11-05T09:23:44.000Z"0c52ce34288e0a7deff8722c84f729a1"5296STANDARD242/17.01.19.Cynata-FUJIFILM-Sign-Strategic-Partnership-Agreement.pdf2018-11-04T23:52:21.000Z"7678da43f288050e1947e706673e6486"176283STANDARD242/conversions/17.01.19.Cynata-FUJIFILM-Sign-Strategic-Partnership-Agreement-thumb.jpg2018-11-05T09:23:45.000Z"2f020e5df33e5850dc9653c096ce151d"4966STANDARD243/17.01.23.Cynata-Succesfully-Completes-Capital-Raising.pdf2018-11-04T23:52:21.000Z"b9af955572f511f69bb7fa173a3671df"166153STANDARD243/conversions/17.01.23.Cynata-Succesfully-Completes-Capital-Raising-thumb.jpg2018-11-05T09:23:45.000Z"5937222489ae77e0634ac968f09c07dc"18079STANDARD244/17.01.25.Appendix-3B-Receipt-of-Funds-Issue-of-Shares-to-Fujifilm.pdf2018-11-04T23:52:21.000Z"32d1b37fee6ee665d6f69554ef5e1526"225671STANDARD244/conversions/17.01.25.Appendix-3B-Receipt-of-Funds-Issue-of-Shares-to-Fujifilm-thumb.jpg2018-11-05T09:23:46.000Z"35766dbfeae6bf2779e5e9e1d0d5c21f"10203STANDARD245/17.01.25.Appendix-4C.pdf2018-11-04T23:52:21.000Z"cddad277a5f7c3f06104fbe51c06f41d"99658STANDARD245/conversions/17.01.25.Appendix-4C-thumb.jpg2018-11-05T09:23:47.000Z"8e2d06856b7f587361e5269373055e56"13683STANDARD246/17.01.25.Cleansing-Notice.pdf2018-11-04T23:52:21.000Z"5ceb1a3ab98a47b5a09345cb7367df50"104342STANDARD246/conversions/17.01.25.Cleansing-Notice-thumb.jpg2018-11-05T09:23:48.000Z"01b59cdf4fa6bd9b2f3033d8ed0704cd"10921STANDARD247/17.01.30.Appendix-3B-Completion-of-Placement.pdf2018-11-04T23:52:21.000Z"e2cd1810c6b3db672c6de52cdbbff368"189242STANDARD247/conversions/17.01.30.Appendix-3B-Completion-of-Placement-thumb.jpg2018-11-05T09:23:49.000Z"710212a656f421ff8df38d0f91f98217"9694STANDARD248/17.01.30.Information-Required-Under-3.10.5A.pdf2018-11-04T23:52:22.000Z"17111d02dc12e6b9ad91f4c8f5184db3"107594STANDARD248/conversions/17.01.30.Information-Required-Under-3.10.5A-thumb.jpg2018-11-05T09:23:50.000Z"d16b63f9679df9197534526336882d5b"14088STANDARD249/17.01.30.Cleansing-Notice.pdf2018-11-04T23:52:22.000Z"dc060be6f8b19008efe17a671e36b382"104129STANDARD249/conversions/17.01.30.Cleansing-Notice-thumb.jpg2018-11-05T09:23:51.000Z"caf053d6be7ea89ee5964bfa191b44dd"10887STANDARD25/conversions/eb57d.13.09.16.ResponsetoASX-thumb.jpg2018-11-06T05:47:31.000Z"f901e73ba64e5ff7d96b91e61ee503c6"5490STANDARD25/eb57d.13.09.16.ResponsetoASX.pdf2018-11-04T23:51:21.000Z"1fb4f7992e9e37f5ce03f20a22592a3c"54616STANDARD250/17.02.02.Positive-Preliminary-Date-from-Preclinical-Heart-Attack-Study.pdf2018-11-04T23:52:22.000Z"34d6131765c86d8fc03f823538b5de5e"173191STANDARD250/conversions/17.02.02.Positive-Preliminary-Date-from-Preclinical-Heart-Attack-Study-thumb.jpg2018-11-05T09:23:52.000Z"a90aec8ffcef9fcf77d2ca513f72636e"18684STANDARD251/17.02.06.Final-GvHD-Preclinical-Report-Confirms-Treatment-Benefit.pdf2018-11-04T23:52:22.000Z"55c4e435319e4a808be385f59fcf03f9"179577STANDARD251/conversions/17.02.06.Final-GvHD-Preclinical-Report-Confirms-Treatment-Benefit-thumb.jpg2018-11-05T09:23:52.000Z"6fe69f0cd212946a6f88434023d5cdd0"18346STANDARD252/17.02.20.Becoming-a-substantial-holder.pdf2018-11-04T23:52:22.000Z"291f3d550b7c53b98f6b3a61e3a1ddfe"1114620STANDARD252/conversions/17.02.20.Becoming-a-substantial-holder-thumb.jpg2018-11-05T09:23:53.000Z"b641d6fcef2c5e15a7645d84f874ac97"10129STANDARD253/17.02.24.Change-in-substantial-holding.pdf2018-11-04T23:52:23.000Z"91f1c05c87fd5d15e74e2ba5993c2b91"1050375STANDARD253/conversions/17.02.24.Change-in-substantial-holding-thumb.jpg2018-11-05T09:23:54.000Z"9823854d596b0286899038a215edaba9"10454STANDARD254/17.02.27.Appendix-4D-Half-Year-Financial-Statements.pdf2018-11-04T23:52:24.000Z"292606148c3c9f08b4bb1e74722ff7a2"585329STANDARD254/conversions/17.02.27.Appendix-4D-Half-Year-Financial-Statements-thumb.jpg2018-11-05T09:23:55.000Z"ba1145a6e7727ae6489cbd320cea8441"15085STANDARD255/17.02.28.Dr-Paul-Wotton-Appointed-as-Chairman-of-Cynata-1.pdf2018-11-04T23:52:24.000Z"862c79648f5bc7c33eabcc6a09708667"172428STANDARD255/conversions/17.02.28.Dr-Paul-Wotton-Appointed-as-Chairman-of-Cynata-1-thumb.jpg2018-11-05T09:23:56.000Z"f969500e3f4fca2c7ae0800d79ea7a2c"16917STANDARD256/17.03.02.Cynata-Advances-Development-of-Cymerus-for-the-Treatment-of-Asthma.pdf2018-11-04T23:52:24.000Z"ae25d8c326d170041297dc5c738f486d"174711STANDARD256/conversions/17.03.02.Cynata-Advances-Development-of-Cymerus-for-the-Treatment-of-Asthma-thumb.jpg2018-11-05T09:23:57.000Z"e9136e2041b167319ada2fd7e462c4d4"17339STANDARD257/17.03.10.Proactive-Investor-Conference-Presentation.pdf2018-11-04T23:52:24.000Z"c7b38bea1ceb5eab8cb1a31bfa54c0ca"1217559STANDARD257/conversions/17.03.10.Proactive-Investor-Conference-Presentation-thumb.jpg2018-11-05T09:23:58.000Z"1b4d555599ee9abe01bdd6c304749e3e"13538STANDARD258/17.03.31.Cynata-Partner-apceth-GmbH-Co-Completes-Cymerus-Evaluation.pdf2018-11-04T23:52:25.000Z"dd792dc1547f7bf2c20c1da4b4e49469"169792STANDARD258/conversions/17.03.31.Cynata-Partner-apceth-GmbH-Co-Completes-Cymerus-Evaluation-thumb.jpg2018-11-05T09:23:58.000Z"5fe71c1366f4f1327b7a4a2350636bd3"14893STANDARD259/17.04.03.Appendix-3Y-Ross-Macdonald.pdf2018-11-04T23:52:25.000Z"5dd0715becb80239add8ac5a3fa44ad4"24428STANDARD259/conversions/17.04.03.Appendix-3Y-Ross-Macdonald-thumb.jpg2018-11-05T09:23:59.000Z"cd2a31d26f3f9a8ff2c2381e2d6654b2"13565STANDARD26/conversions/fb9d5.13.09.10.SubstantialShar-thumb.jpg2018-11-06T05:47:32.000Z"9f7ea4b7fdcfdcc5fa7e0e9a27d2fd88"13578STANDARD26/fb9d5.13.09.10.SubstantialShar.pdf2018-11-04T23:51:22.000Z"a85c4b336615ec4909c1704592e330ad"2095487STANDARD260/17.04.11.CYP-in-Collaboration-on-Acute-Respiratory-Distress-Syndrome.pdf2018-11-04T23:52:25.000Z"61da432d64f09c750efb06374c236cf7"191324STANDARD260/conversions/17.04.11.CYP-in-Collaboration-on-Acute-Respiratory-Distress-Syndrome-thumb.jpg2018-11-05T09:24:00.000Z"8f2ff7729a0111cecff154db01134199"18197STANDARD261/17.04.12.Cynata-Files-for-New-Patent-for-Oncology-Applications.pdf2018-11-04T23:52:26.000Z"0b0d413e354a0cb2322d2be3ac1307cb"167066STANDARD261/conversions/17.04.12.Cynata-Files-for-New-Patent-for-Oncology-Applications-thumb.jpg2018-11-05T09:24:01.000Z"8fd57dbcd4af8fe08ea3fad349e24232"18546STANDARD262/17.04.19.Cynata-Advances-to-Pre-IND-Meeting-with-US-FDA-1.pdf2018-11-04T23:52:26.000Z"b7e67da3a2b7ed1c77b18c97d02e5641"171413STANDARD262/conversions/17.04.19.Cynata-Advances-to-Pre-IND-Meeting-with-US-FDA-1-thumb.jpg2018-11-05T09:24:01.000Z"eeabdfdf8d2924b2f2f644c5688bb40f"16057STANDARD263/17.04.26.March-2017-Quarterly-Report.pdf2018-11-04T23:52:26.000Z"3b8e502910e02646a3b8be3cec1babee"313472STANDARD263/conversions/17.04.26.March-2017-Quarterly-Report-thumb.jpg2018-11-05T09:24:02.000Z"5082a3785ee8306c6eb318b71890e87f"16064STANDARD264/17.05.03.Appendix-3Y-Stewart-Washer.pdf2018-11-04T23:52:26.000Z"5179a2801074baff9fd5b23c6da53552"25096STANDARD264/conversions/17.05.03.Appendix-3Y-Stewart-Washer-thumb.jpg2018-11-05T09:24:03.000Z"288b85c437e72d7b90d1ac01c4296aaa"13905STANDARD265/17.05.04-Cyanta-Presentation-Webcast.pdf2018-11-04T23:52:26.000Z"70ee91c1891c617ced2acf178caa9909"166998STANDARD265/conversions/17.05.04-Cyanta-Presentation-Webcast-thumb.jpg2018-11-05T09:24:04.000Z"828835578de46c46c4bf8ad967ada205"16350STANDARD266/17.05.08.Appendix-3Y-Paul-Wotton.pdf2018-11-04T23:52:26.000Z"b784da23736daa3b3e3ceea2372bfda1"24714STANDARD266/conversions/17.05.08.Appendix-3Y-Paul-Wotton-thumb.jpg2018-11-05T09:24:04.000Z"da5802bde2b4a0d5ab38cc1d06ce14ed"13160STANDARD267/17.05.08.Shaw-Partners-Initiates-Cynata-Research-Coverage.pdf2018-11-04T23:52:26.000Z"0ec12c7c74dfd4fd5f8be6db1ade05d4"159723STANDARD267/conversions/17.05.08.Shaw-Partners-Initiates-Cynata-Research-Coverage-thumb.jpg2018-11-05T09:24:05.000Z"ba08f514a8eda52391c75247c5c97f40"12251STANDARD268/17.05.10.Interview-with-UK-Chief-Investigator-in-Cynata-Clinical-Trial.pdf2018-11-04T23:52:27.000Z"ab8ff91d947d10cbb51f22f2601669d1"167814STANDARD268/conversions/17.05.10.Interview-with-UK-Chief-Investigator-in-Cynata-Clinical-Trial-thumb.jpg2018-11-05T09:24:06.000Z"905c694eb3861a2743b4db32d1e81f2f"15495STANDARD269/17.05.16.Treatment-Commences-in-Cynatas-World-First-Clinical-Trial.pdf2018-11-04T23:52:27.000Z"5129b96c63488d97aa172ef6178085ce"214715STANDARD269/conversions/17.05.16.Treatment-Commences-in-Cynatas-World-First-Clinical-Trial-thumb.jpg2018-11-05T09:24:07.000Z"666031e780c35a85c1a167db64f7f75f"18174STANDARD27/bc6eb.13.09.03.Section708ANot.pdf2018-11-04T23:51:22.000Z"ee80505314c8d3d285dec3a37c343bb6"84529STANDARD27/conversions/bc6eb.13.09.03.Section708ANot-thumb.jpg2018-11-06T05:47:33.000Z"9546ce88ccb50a75850c7ff4dd9591e8"5202STANDARD270/17.05.17.Appendix-3Y-John-Chiplin.pdf2018-11-04T23:52:27.000Z"3d951c2e8ea87a16e11ba0a635bd44ed"23917STANDARD270/conversions/17.05.17.Appendix-3Y-John-Chiplin-thumb.jpg2018-11-05T09:24:08.000Z"14c7404523060aa7209bd2707d476e24"12749STANDARD271/17.05.26.Appendix-3Y-Paul-Wotton-1.pdf2018-11-04T23:52:27.000Z"3ebb4573ad43a7ea47a7b3226ea4109c"24597STANDARD271/conversions/17.05.26.Appendix-3Y-Paul-Wotton-1-thumb.jpg2018-11-05T09:24:08.000Z"3346d2e8e39bec5f2c7f426c9b7ba2bd"13126STANDARD272/17.05.29.Cynata-Investor-Presentation-May-2017.pdf2018-11-04T23:52:27.000Z"5d3622e5c804db3d82a68596b6383274"895241STANDARD272/conversions/17.05.29.Cynata-Investor-Presentation-May-2017-thumb.jpg2018-11-05T09:24:10.000Z"07c6e44e12aabfefb519d5b57bcfa7cf"14964STANDARD273/17.05.29.Cynata-Investor-Presentation-May-2017-1.pdf2018-11-04T23:52:28.000Z"5d3622e5c804db3d82a68596b6383274"895241STANDARD273/conversions/17.05.29.Cynata-Investor-Presentation-May-2017-1-thumb.jpg2018-11-05T09:24:11.000Z"07c6e44e12aabfefb519d5b57bcfa7cf"14964STANDARD274/17.06.02.Correction-to-date-in-Appendix-3Y-lodged-26-May-2017.pdf2018-11-04T23:52:28.000Z"a03fb011600775fde196449d02699ca5"24659STANDARD274/conversions/17.06.02.Correction-to-date-in-Appendix-3Y-lodged-26-May-2017-thumb.jpg2018-11-05T09:24:12.000Z"c351b1e5480e1556d905188ccdb4b7f1"13128STANDARD275/17.06.02.Appendix-3Y-Peter-Webse.pdf2018-11-04T23:52:28.000Z"727a183193a08c92c4161d7098ae3ffc"24920STANDARD275/conversions/17.06.02.Appendix-3Y-Peter-Webse-thumb.jpg2018-11-05T09:24:12.000Z"46db6c1b53ea97ba80ab5d5a890531d1"12884STANDARD276/17.06.07.Van-Leeuwenhoeck-Institute-Initiates-Cynata-Research-Coverage.pdf2018-11-04T23:52:28.000Z"4893763fa36a551eede22130978f45a1"162917STANDARD276/conversions/17.06.07.Van-Leeuwenhoeck-Institute-Initiates-Cynata-Research-Coverage-thumb.jpg2018-11-05T09:24:13.000Z"f3cafe6f22547fd683eba3473f3e75fe"13361STANDARD277/17.06.19.United-States-Patent-for-Core-Cynata-Technology.pdf2018-11-04T23:52:29.000Z"34c6cf0628257b862cf83cbc8a41fedc"183885STANDARD277/conversions/17.06.19.United-States-Patent-for-Core-Cynata-Technology-thumb.jpg2018-11-05T09:24:14.000Z"794a0e334323d6821bde303b04247214"16815STANDARD278/17.06.20.Cynata-Files-New-Patent-Application-for-Cymerus-in-Oncology.pdf2018-11-04T23:52:29.000Z"2fba2bfbe0b9fb178eb6da603ce1b450"191432STANDARD278/conversions/17.06.20.Cynata-Files-New-Patent-Application-for-Cymerus-in-Oncology-thumb.jpg2018-11-05T09:24:15.000Z"b57050a7e9bd77d18e04181af523b65b"15006STANDARD279/17.06.22.CYP-MSC-Data-in-Asthma-Model-Published-in-Scientific-Journal.pdf2018-11-04T23:52:29.000Z"f7f36aa531924dd52196e08241471dc7"235857STANDARD279/conversions/17.06.22.CYP-MSC-Data-in-Asthma-Model-Published-in-Scientific-Journal-thumb.jpg2018-11-05T09:24:17.000Z"3fd3f01f47b1962accd1dcd7385f0a85"18132STANDARD28/conversions/e9dcc.13.08.30.Section708ANot-thumb.jpg2018-11-06T05:47:34.000Z"cbd34d7511d03b7c8892868fa6b0d95b"5193STANDARD28/e9dcc.13.08.30.Section708ANot.pdf2018-11-04T23:51:22.000Z"0f4ff5f5cb0ac10e87e6f2075d2f7c65"84300STANDARD280/17.06.27.Cynata-Therapeutics-GvHD-Clinical-Trial-Corporate-Progress.pdf2018-11-04T23:52:29.000Z"6dc07e49956b1b075aef969867831429"181539STANDARD280/conversions/17.06.27.Cynata-Therapeutics-GvHD-Clinical-Trial-Corporate-Progress-thumb.jpg2018-11-05T09:24:18.000Z"2d6bfb1ecd51caba843685f66bdaa56d"20764STANDARD281/17.07.04.Change-of-Address.pdf2018-11-04T23:52:30.000Z"ae6cc04c7f7b7fac3dc5bc9c1a3e0d86"120339STANDARD281/conversions/17.07.04.Change-of-Address-thumb.jpg2018-11-05T09:24:18.000Z"d7e11844f471726a77e1ed5f0a9e5c69"6559STANDARD282/17.07.05.FDA-Meeting-Provides-Clear-Path-for-US-Development-Plans.pdf2018-11-04T23:52:30.000Z"d886cef60f337d50ca8766b069b80498"172123STANDARD282/conversions/17.07.05.FDA-Meeting-Provides-Clear-Path-for-US-Development-Plans-thumb.jpg2018-11-05T09:24:19.000Z"3e67a3dc1d837707989d1fac7717ae72"18866STANDARD283/17.07.24.NDFs-Stuart-Roberts-Initiates-Cynata-Research-Coverage.pdf2018-11-04T23:52:30.000Z"e61e4b1e4f4c4a36908a7c9ff393fe69"161474STANDARD283/conversions/17.07.24.NDFs-Stuart-Roberts-Initiates-Cynata-Research-Coverage-thumb.jpg2018-11-05T09:24:20.000Z"8420f956b7663163488134378a3c3c11"11637STANDARD284/17.07.28.June-2017-Quarterly-Report.pdf2018-11-04T23:52:30.000Z"3324aedeb0bdb1b9c94c869a8ace596b"290070STANDARD284/conversions/17.07.28.June-2017-Quarterly-Report-thumb.jpg2018-11-05T09:24:21.000Z"55090f682bc4e22cf55f5b76eb7e413f"18076STANDARD285/17.08.07.Appendix-3B.pdf2018-11-04T23:52:31.000Z"5d0c9a89c824a6032e3dc8fdcdb892fd"272972STANDARD285/conversions/17.08.07.Appendix-3B-thumb.jpg2018-11-05T09:24:22.000Z"66153bd159744eb6befd262585cd5205"11678STANDARD286/17.08.23.Positive-Data-from-CYP-MSCs-in-2nd-Preclinical-Asthma-Study.pdf2018-11-04T23:52:31.000Z"cca8c94aba6fc6e34e7d51b6e1c595fd"232127STANDARD286/conversions/17.08.23.Positive-Data-from-CYP-MSCs-in-2nd-Preclinical-Asthma-Study-thumb.jpg2018-11-05T09:24:22.000Z"20582d657ce499b481ec978b789c26f5"18940STANDARD287/17.08.24.Appendix-4E-Annual-Financial-Statements.pdf2018-11-04T23:52:31.000Z"9740fb3ec5da9bf513891ea0786a20ad"1029368STANDARD287/conversions/17.08.24.Appendix-4E-Annual-Financial-Statements-thumb.jpg2018-11-05T09:24:23.000Z"59028c27dfbd80c50fa458595cf1bc5c"14049STANDARD288/17.08.24.Appendix-4G.pdf2018-11-04T23:52:31.000Z"96e498e4acd7d3fdc0730434a048ca43"178420STANDARD288/conversions/17.08.24.Appendix-4G-thumb.jpg2018-11-05T09:24:24.000Z"4009670fc8744f96691c4bbae9229e70"3579STANDARD289/17.08.31.Health-Canada-Meeting-Advances-CYP-Global-Development-Plans.pdf2018-11-04T23:52:32.000Z"a9a0fa0cd57db31e99a03a39b6b2db19"169937STANDARD289/conversions/17.08.31.Health-Canada-Meeting-Advances-CYP-Global-Development-Plans-thumb.jpg2018-11-05T09:24:25.000Z"786dd3755f8e56ef6224f8c7f1fc1d65"16776STANDARD29/21423.13.08.29.Section708ANot.pdf2018-11-04T23:51:22.000Z"6129ad3c91c5adf0269accb66c753416"85565STANDARD29/conversions/21423.13.08.29.Section708ANot-thumb.jpg2018-11-06T05:47:34.000Z"48bf05dc3b90a91550156bc9ea0749a2"13267STANDARD290/17.09.11.HC-Wainwrigh-^0-Co-Updates-CYP-Research-Coverage.pdf2018-11-04T23:52:32.000Z"aca08a323f717f12fa5f4e2a5995511d"161980STANDARD290/conversions/17.09.11.HC-Wainwrigh-^0-Co-Updates-CYP-Research-Coverage-thumb.jpg2018-11-05T09:24:26.000Z"3935eb731efdeb3f5e681a7f2321fa9c"10073STANDARD291/17.09.27.US-Patent-Granted-for-Cynata-Cymerus-Technology.pdf2018-11-04T23:52:32.000Z"13c366e1798b2f0961894e18a42ca0bc"182392STANDARD291/conversions/17.09.27.US-Patent-Granted-for-Cynata-Cymerus-Technology-thumb.jpg2018-11-05T09:24:26.000Z"936ec14b8e680ab2200a74f20282c616"15147STANDARD292/17.10.09.Cynata-to-Increase-Exposure-in-Japan.pdf2018-11-04T23:52:32.000Z"d2105afa01871dd90614e6877370b54e"213869STANDARD292/conversions/17.10.09.Cynata-to-Increase-Exposure-in-Japan-thumb.jpg2018-11-05T09:24:27.000Z"5b53eb077ae8b6911f1a9b18362651de"16412STANDARD293/17.10.09.Notice-of-AGM-and-Proxy-Form.pdf2018-11-04T23:52:32.000Z"1641ab1f680dfbd4e0ec3fbcc842bcb1"1143216STANDARD293/conversions/17.10.09.Notice-of-AGM-and-Proxy-Form-thumb.jpg2018-11-05T09:24:28.000Z"4470cbd1d1c967aa627f99dad45118fd"8041STANDARD294/17.10.09.Annual-Report-to-Shareholders.pdf2018-11-04T23:52:34.000Z"d29258d37b0ee4a4f0dc390065054907"1032731STANDARD294/conversions/17.10.09.Annual-Report-to-Shareholders-thumb.jpg2018-11-05T09:24:30.000Z"31998912253cb20bbc1c59b589b801cf"4955STANDARD295/17.10.09.Annual-Report-to-Shareholders-1.pdf2018-11-04T23:52:34.000Z"d29258d37b0ee4a4f0dc390065054907"1032731STANDARD295/conversions/17.10.09.Annual-Report-to-Shareholders-1-thumb.jpg2018-11-05T09:24:31.000Z"31998912253cb20bbc1c59b589b801cf"4955STANDARD296/17.10.11.Van-Leeuwenhoek-Research-Analysis.pdf2018-11-04T23:52:34.000Z"4e36ae447dfde4d0c2b013dc5f41a58b"180054STANDARD296/conversions/17.10.11.Van-Leeuwenhoek-Research-Analysis-thumb.jpg2018-11-05T09:24:31.000Z"e4852470bb6df25a4904a62a30ca7de1"11837STANDARD297/17.10.27.September-2017-Quarterly-Report.pdf2018-11-04T23:52:35.000Z"9865ec637c3c08dc55af029db3f69420"550211STANDARD297/conversions/17.10.27.September-2017-Quarterly-Report-thumb.jpg2018-11-05T09:24:32.000Z"1d6888d6e598faf4ca8e66f6471f8053"16887STANDARD298/17.10.27.September-2017-Quarterly-Report-1.pdf2018-11-04T23:52:35.000Z"7285cb61b83c8d47e2c02d102ff6fabd"645838STANDARD298/conversions/17.10.27.September-2017-Quarterly-Report-1-thumb.jpg2018-11-05T09:24:33.000Z"1e418afe11106295b5a89c0f74f4e908"9246STANDARD299/17.11.15.Enrolment-Completed-in-1st-Cohort-of-Cynata-Clincial-Trial.pdf2018-11-04T23:52:35.000Z"e5294494d50a661542aa748687ac731b"207085STANDARD299/conversions/17.11.15.Enrolment-Completed-in-1st-Cohort-of-Cynata-Clincial-Trial-thumb.jpg2018-11-05T09:24:34.000Z"1812e04b083c101264da45d117785360"16781STANDARD3/conversions/e7ef5.BBYResearchUpdate-thumb.jpg2018-11-06T05:47:14.000Z"a2264e83f82efde123ce29b4d65dfabf"12290STANDARD3/e7ef5.BBYResearchUpdate.pdf2018-11-04T11:20:04.000Z"415e38b6088ab6e630cf5f226b2db393"46234STANDARD30/97101.13.08.29.Appendix-3B.pdf2018-11-04T23:51:23.000Z"7b1c5c6e0f78727c49a84cc0aaa54174"128047STANDARD30/conversions/97101.13.08.29.Appendix-3B-thumb.jpg2018-11-06T05:47:35.000Z"d3561361cb8df7bdc26c98ef5e634c48"10480STANDARD300/17.11.15.Company-Investor-Presentation.pdf2018-11-04T23:52:36.000Z"dae90504e5cb2324b6ba1aab762789f7"1031272STANDARD300/conversions/17.11.15.Company-Investor-Presentation-thumb.jpg2018-11-05T09:24:35.000Z"191ad5b4c9696efe22dc638463b2a2ce"17482STANDARD301/17.11.17.Chairmans-AGM-Address.pdf2018-11-04T23:52:36.000Z"291cc878aae4290c5bb52317e55cc0ec"148715STANDARD301/conversions/17.11.17.Chairmans-AGM-Address-thumb.jpg2018-11-05T09:24:36.000Z"06345b50396bfaf3ac931929ea7ab117"18551STANDARD302/17.11.17.Managing-Directors-AGM-Presentation.pdf2018-11-04T23:52:37.000Z"927dcdd3cb581606023e7e24fe6d069c"685760STANDARD302/conversions/17.11.17.Managing-Directors-AGM-Presentation-thumb.jpg2018-11-05T09:24:37.000Z"55b9d2bcb7e632729cab55306a093cb0"14513STANDARD303/17.11.17.Results-of-AGM.pdf2018-11-04T23:52:37.000Z"a3d3ec7d8709c2ffe5fe20121818fb91"228249STANDARD303/conversions/17.11.17.Results-of-AGM-thumb.jpg2018-11-05T09:24:38.000Z"096cb3a303d8171a97a82516fef1b156"7834STANDARD304/17.11.17.Appendix-3B.pdf2018-11-04T23:52:37.000Z"73c6520a41d1f49abdc14f9fe517655d"194279STANDARD304/conversions/17.11.17.Appendix-3B-thumb.jpg2018-11-05T09:24:38.000Z"7ad7cd2e5c8bf31075e246aa8864f452"12797STANDARD305/17.11.17.Appendix-3Y-Paul-Wotton.pdf2018-11-04T23:52:37.000Z"97d86be9d4d5993fc160e339567a7c1c"25903STANDARD305/conversions/17.11.17.Appendix-3Y-Paul-Wotton-thumb.jpg2018-11-05T09:24:39.000Z"47ea66dee90aa3ad2afdcd298eafa047"13298STANDARD306/17.12.07.United-States-Patent-Allowance-for-Core-Cynata-Technology.pdf2018-11-04T23:52:38.000Z"0287eb30fcf8b103e68c60ec24bfe8a3"186026STANDARD306/conversions/17.12.07.United-States-Patent-Allowance-for-Core-Cynata-Technology-thumb.jpg2018-11-05T09:24:40.000Z"858df70728a1826a87a38c47ad73e9a3"16228STANDARD307/17.12.11.Final-Preclinical-Asthma-Study-Confirms-Efficacy.pdf2018-11-04T23:52:38.000Z"a915f6a9913e65dfcb6bb021a1ce3ddc"246334STANDARD307/conversions/17.12.11.Final-Preclinical-Asthma-Study-Confirms-Efficacy-thumb.jpg2018-11-05T09:24:41.000Z"8fde8e7ce23bc12912ffd66b67d8ed8b"17251STANDARD308/17.12.14.Cynata-Receives-1.3m-RD-Tax-Incentive-Refund.pdf2018-11-04T23:52:40.000Z"482921366b302fb54e843eb09cacdf2f"184780STANDARD308/conversions/17.12.14.Cynata-Receives-1.3m-RD-Tax-Incentive-Refund-thumb.jpg2018-11-05T09:24:42.000Z"64db686eea9c614be8262d687eb8f938"12702STANDARD309/17.12.18.End-of-year-Newsletter-2018-Outlook.pdf2018-11-04T23:52:41.000Z"66dd49b8da72da5d55238ec0c75f497a"212148STANDARD309/conversions/17.12.18.End-of-year-Newsletter-2018-Outlook-thumb.jpg2018-11-05T09:24:43.000Z"f20cd36686c7116d9b81284ed27bd228"15963STANDARD31/33480.13.08.28.PreliminaryFina.pdf2018-11-04T23:51:23.000Z"07d38c7961cdae1c600464aac6eb2e3a"2255885STANDARD31/conversions/33480.13.08.28.PreliminaryFina-thumb.jpg2018-11-06T05:47:36.000Z"8820abb371d87caabf2bfcf45b5c53c5"13671STANDARD310/18.01.11.Interview-with-Cynata-Co-Founder-Professor-Slukvin.pdf2018-11-04T23:52:41.000Z"e38afd63a48e3e5ae417ae1ec6b37796"187636STANDARD310/conversions/18.01.11.Interview-with-Cynata-Co-Founder-Professor-Slukvin-thumb.jpg2018-11-05T09:24:43.000Z"679600989c10796c02250a3ff1d30da7"17722STANDARD311/18.01.11.Release-of-Securities-from-Voluntary-Escrow.pdf2018-11-04T23:52:41.000Z"4df25cf4991ea2c813cbf7fca7015b8c"181776STANDARD311/conversions/18.01.11.Release-of-Securities-from-Voluntary-Escrow-thumb.jpg2018-11-05T09:24:44.000Z"e3b76df17853a734c4a033896c5761da"11130STANDARD312/18.01.22.Encouraging-Early-Data-Cynata-Clinical-Trial-Proceeds.pdf2018-11-04T23:52:41.000Z"ec71365d655408154d18f3bbde9bea35"218711STANDARD312/conversions/18.01.22.Encouraging-Early-Data-Cynata-Clinical-Trial-Proceeds-thumb.jpg2018-11-05T09:24:45.000Z"3c7d543af01c0e0657cb0b7de246ff94"17052STANDARD313/18.01.23.Lapse-of-Unlisted-Options.pdf2018-11-04T23:52:41.000Z"0ad259ddc249ef4a3a3b80acfe706865"101777STANDARD313/conversions/18.01.23.Lapse-of-Unlisted-Options-thumb.jpg2018-11-05T09:24:46.000Z"7bf49b268307203957ea3392c7e6c2e8"7700STANDARD314/18.01.23.Cynata-Celularity-Inc-Execute-MOU.pdf2018-11-04T23:52:42.000Z"ed76341d6080e0f6a54c31b566d059b3"213006STANDARD314/conversions/18.01.23.Cynata-Celularity-Inc-Execute-MOU-thumb.jpg2018-11-05T09:24:47.000Z"c9b7208e0a0c9e98b44ff5145ea3c5ac"17895STANDARD315/18.01.24.Cynata-Treats-First-Patient-in-Cohort-B.pdf2018-11-04T23:52:42.000Z"ed46971775eca1dda76dcabc1bcb040f"212124STANDARD315/conversions/18.01.24.Cynata-Treats-First-Patient-in-Cohort-B-thumb.jpg2018-11-05T09:24:47.000Z"8fd54d1de6113fadd2f20d3374f5e1fe"17673STANDARD316/18.01.30.December-2017-Quarterly-Report.pdf2018-11-04T23:52:42.000Z"cf73e92d347140e27937c0f7f46684d6"305240STANDARD316/conversions/18.01.30.December-2017-Quarterly-Report-thumb.jpg2018-11-05T09:24:48.000Z"1a0d632b3c340fb1f5160105b6411f74"15194STANDARD317/18.01.30.December-2017-Quarterly-Report-1.pdf2018-11-04T23:52:42.000Z"cf73e92d347140e27937c0f7f46684d6"305240STANDARD317/conversions/18.01.30.December-2017-Quarterly-Report-1-thumb.jpg2018-11-05T09:24:49.000Z"1a0d632b3c340fb1f5160105b6411f74"15194STANDARD318/18.02.05.Cynata-Engineered-MSC-Study-Review-Reveals-Promising-Results.pdf2018-11-04T23:52:43.000Z"1770ec3112311a85347cc7288a833c3d"195451STANDARD318/conversions/18.02.05.Cynata-Engineered-MSC-Study-Review-Reveals-Promising-Results-thumb.jpg2018-11-05T09:24:50.000Z"07df7b63de4bdd98174c43f1fe1c32a3"16454STANDARD319/18.02.27.Excellent-Data-from-Final-Preliminary-Evaluation-Period.pdf2018-11-04T23:52:43.000Z"95d375b2824becdb25c874f169661b25"221035STANDARD319/conversions/18.02.27.Excellent-Data-from-Final-Preliminary-Evaluation-Period-thumb.jpg2018-11-05T09:24:51.000Z"6ad34571de5654f56d2ffa6173324b9a"15605STANDARD32/c62ed.13.08.28.Appendix3B-Exer.pdf2018-11-04T23:51:25.000Z"d9f0091a67953a78942e758112f5ae9f"127902STANDARD32/conversions/c62ed.13.08.28.Appendix3B-Exer-thumb.jpg2018-11-06T05:47:37.000Z"82064f9fffbddf9d48fa448ea560c7ed"10479STANDARD320/18.02.27.Appendix-4DHalf-Year-Financial-Statements.pdf2018-11-04T23:52:43.000Z"6a12bcbc21a944886e9112239b1d8b22"610772STANDARD320/conversions/18.02.27.Appendix-4DHalf-Year-Financial-Statements-thumb.jpg2018-11-05T09:24:51.000Z"e333d7a01d40a0c8db7ddc732f6f73fd"15034STANDARD321/18.02.28.Appendix-3B.pdf2018-11-04T23:52:43.000Z"86e57b3d26e4d8d634e04a1e0d858411"192808STANDARD321/conversions/18.02.28.Appendix-3B-thumb.jpg2018-11-05T09:24:52.000Z"6b34acb1e277ab8493bf87f51e0fdbc0"11835STANDARD322/18.02.28.Cleansing-Notice.pdf2018-11-04T23:52:43.000Z"a87ab9c269cace8ce182499dbfe3b6cc"104886STANDARD322/conversions/18.02.28.Cleansing-Notice-thumb.jpg2018-11-05T09:24:53.000Z"fe02a4f2f07c9ee3f6b28f917d85ec1b"10599STANDARD323/18.03.12.Shaw-and-Partners-Update-Cynata-Research-Coverage.pdf2018-11-04T23:52:44.000Z"23655397df697500e7edd987b8a0632f"161349STANDARD323/conversions/18.03.12.Shaw-and-Partners-Update-Cynata-Research-Coverage-thumb.jpg2018-11-05T09:24:54.000Z"97f88a2202e2caa6b2c6500ef4e9e04d"11583STANDARD324/18.03.13.Updated-Top-20-Shareholders.pdf2018-11-04T23:52:44.000Z"8d0482e715d0d4b126455074fabe20ef"70322STANDARD324/conversions/18.03.13.Updated-Top-20-Shareholders-thumb.jpg2018-11-05T09:24:54.000Z"9b53c9208498b4c2bb9db0bcb98e7844"13913STANDARD325/18.03.13.Appendix-3B.pdf2018-11-04T23:52:44.000Z"1ccd17f1afb1e7dafca074ac0d45ce17"192934STANDARD325/conversions/18.03.13.Appendix-3B-thumb.jpg2018-11-05T09:24:55.000Z"ddacfbc41edb2d6fa6d39d21fe4fdb3e"11841STANDARD326/18.03.13.Cleansing-Notice.pdf2018-11-04T23:52:44.000Z"9f0c1c24acb5fde1c506ca0f7815ceb2"104861STANDARD326/conversions/18.03.13.Cleansing-Notice-thumb.jpg2018-11-05T09:24:56.000Z"265e9ef4e39597ad11622b353b6a07eb"10580STANDARD327/18.03.28.FDA-Grants-Orphan-Drug-Designation-to-Cynata-for-CYP-001.pdf2018-11-04T23:52:44.000Z"9aa44f62b5894cf6ab1e8beec859a6c8"207688STANDARD327/conversions/18.03.28.FDA-Grants-Orphan-Drug-Designation-to-Cynata-for-CYP-001-thumb.jpg2018-11-05T09:24:57.000Z"2b27416a38f145bdaf9397451211daa5"16283STANDARD328/18.03.28.Appendix-3B.pdf2018-11-04T23:52:44.000Z"9606f21fe581d215de66fce00b5ed2e3"192985STANDARD328/conversions/18.03.28.Appendix-3B-thumb.jpg2018-11-05T09:24:57.000Z"f03f32fd1416682f87cc6aa0f41de068"11839STANDARD329/18.03.28.Cleansing-Notice.pdf2018-11-04T23:52:45.000Z"6ed62fc79c2dc94efd3aa8fcd77eead0"104422STANDARD329/conversions/18.03.28.Cleansing-Notice-thumb.jpg2018-11-05T09:24:58.000Z"1004dd5a484c90a3353ec5062a921bb4"10588STANDARD33/c8685.13.08.27.SPPClosedEarly.pdf2018-11-04T23:51:25.000Z"17316b3231032267811c9cbfb8ab5cc8"164909STANDARD33/conversions/c8685.13.08.27.SPPClosedEarly-thumb.jpg2018-11-06T05:47:37.000Z"1e07097b2bd453da6179f6946ef3b846"8794STANDARD330/18.04.04.Appendix-3B.pdf2018-11-04T23:52:46.000Z"7c7995801324b46fb3dd322e314d5be8"193009STANDARD330/conversions/18.04.04.Appendix-3B-thumb.jpg2018-11-05T09:24:59.000Z"f03f32fd1416682f87cc6aa0f41de068"11839STANDARD331/18.04.04.Cleansing-Notice.pdf2018-11-04T23:52:46.000Z"3980646313cbbc2acd326c17d993a339"104417STANDARD331/conversions/18.04.04.Cleansing-Notice-thumb.jpg2018-11-05T09:24:59.000Z"d30de076c6ff2393efe286ecfa9c48fa"10514STANDARD332/18.04.11.Further-US-Patent-Granted-for-Cynata-Cymerus-Technology.pdf2018-11-04T23:52:46.000Z"608b584acfb2d11749e2566af6a4843a"166132STANDARD332/conversions/18.04.11.Further-US-Patent-Granted-for-Cynata-Cymerus-Technology-thumb.jpg2018-11-05T09:25:00.000Z"92f55952cf956bbaac0cbb51534f16a0"16613STANDARD333/18.04.12.Cynata-to-Present-at-ARM-Investor-Day.pdf2018-11-04T23:52:46.000Z"57cb7dc3e2c0cc5f1993a7d1fd1f03c1"191998STANDARD333/conversions/18.04.12.Cynata-to-Present-at-ARM-Investor-Day-thumb.jpg2018-11-05T09:25:01.000Z"1550799194ee02b6da986480f2bc8f0c"15598STANDARD334/18.04.20.CYP-Completes-Patent-Application-related-to-CAR-T-Therapy.pdf2018-11-04T23:52:47.000Z"0e9a21718c1ec00df257faf095fb6b8c"173396STANDARD334/conversions/18.04.20.CYP-Completes-Patent-Application-related-to-CAR-T-Therapy-thumb.jpg2018-11-05T09:25:02.000Z"bd9c60afbd9d3fd44d465df64e747078"19017STANDARD335/CYP-Investor-Presentation-v14.pdf2018-11-04T23:52:47.000Z"e453b92e7cadff5b90f83f7590a044dd"7529177STANDARD335/conversions/CYP-Investor-Presentation-v14-thumb.jpg2018-11-05T09:25:06.000Z"06d8b3ce5d984dd64c5726df4e96ebd2"14846STANDARD336/18.04.24.Appendix-3B.pdf2018-11-04T23:52:49.000Z"118986a6d32d20f635a539cdfa07c477"193176STANDARD336/conversions/18.04.24.Appendix-3B-thumb.jpg2018-11-05T09:25:06.000Z"c89c3bb7683805aa1c9373451f81a2e2"11835STANDARD337/18.04.24.Cleansing-Notice.pdf2018-11-04T23:52:50.000Z"1fb6433639da7594f0f61ddcb5aa7210"104136STANDARD337/conversions/18.04.24.Cleansing-Notice-thumb.jpg2018-11-05T09:25:07.000Z"79534310cf83504b07844d82a4abef08"10565STANDARD338/18.04.27.March-2018-Quarterly-Report.pdf2018-11-04T23:52:50.000Z"2e64f7b60be3336892bf8f1d3ceecea5"281579STANDARD338/conversions/18.04.27.March-2018-Quarterly-Report-thumb.jpg2018-11-05T09:25:08.000Z"4b0eaeb327141b6b9058140eb442f4e3"16008STANDARD339/18.04.27.March-2018-Quarterly-Report-1.pdf2018-11-04T23:52:50.000Z"2e64f7b60be3336892bf8f1d3ceecea5"281579STANDARD339/conversions/18.04.27.March-2018-Quarterly-Report-1-thumb.jpg2018-11-05T09:25:09.000Z"4b0eaeb327141b6b9058140eb442f4e3"16008STANDARD34/972fa.13.08.27.Notice-of-Meetin.pdf2018-11-04T23:51:25.000Z"9c10513c12568b569975b9f168df4fb1"112331STANDARD34/conversions/972fa.13.08.27.Notice-of-Meetin-thumb.jpg2018-11-06T05:47:38.000Z"243d46038cdbd0d3c0145e1e79a7ae61"7128STANDARD340/18.05.07.Notice-of-Allowance-from-EPO-for-Patent-Application.pdf2018-11-04T23:52:50.000Z"0063a41e8b80fb3d4f3960db9b087f8b"186088STANDARD340/conversions/18.05.07.Notice-of-Allowance-from-EPO-for-Patent-Application-thumb.jpg2018-11-05T09:25:09.000Z"329e7dc4fefc6908428fefa2e4e1a928"17420STANDARD341/18.05.07.Becoming-a-substantial-holder.pdf2018-11-04T23:52:50.000Z"e4da893d481c7b749ceed445ab3b71ca"294015STANDARD341/conversions/18.05.07.Becoming-a-substantial-holder-thumb.jpg2018-11-05T09:25:10.000Z"0e9a477f9cfd50aab4cf6fc1122bb6c4"14354STANDARD342/18.05.15.Appendix-3B.pdf2018-11-04T23:52:51.000Z"d03b236ca320ee9855482e08624b7bd5"193275STANDARD342/conversions/18.05.15.Appendix-3B-thumb.jpg2018-11-05T09:25:11.000Z"6dd42b93fe7051dc4a3f427c92b93576"11851STANDARD343/18.05.15.Cleansing-Notice.pdf2018-11-04T23:52:51.000Z"ed6bc2e11cfd5b1cde9a4483ec187982"104400STANDARD343/conversions/18.05.15.Cleansing-Notice-thumb.jpg2018-11-05T09:25:11.000Z"34273df489bc5b21acfcc0539e3a7358"10520STANDARD344/18.05.22.Appendix-3B.pdf2018-11-04T23:52:51.000Z"c3219aaab8ea70864d8ae73c815edd4c"193242STANDARD344/conversions/18.05.22.Appendix-3B-thumb.jpg2018-11-05T09:25:12.000Z"6dd42b93fe7051dc4a3f427c92b93576"11851STANDARD345/18.05.22.Cleansing-Notice.pdf2018-11-04T23:52:51.000Z"caec4dcb91f3eb12923442a9044eaddf"104409STANDARD345/conversions/18.05.22.Cleansing-Notice-thumb.jpg2018-11-05T09:25:13.000Z"3cafd957715e11f638fe41a2c9fe8b8a"10527STANDARD346/18.05.24.Enrolment-Completed-in-Cynatas-Phase-1-Clinical-Trial.pdf2018-11-04T23:52:51.000Z"1a3296bb28c5f5321794217ab413a59a"210754STANDARD346/conversions/18.05.24.Enrolment-Completed-in-Cynatas-Phase-1-Clinical-Trial-thumb.jpg2018-11-05T09:25:14.000Z"ecc86161ca8ac9524090bcd620db9dac"16064STANDARD347/18.05.30.5.2m-placement-of-shares-to-Fidelity-International.pdf2018-11-04T23:52:51.000Z"e9ebd2c94a6c9aacf88ac5f6255ef8f8"169512STANDARD347/conversions/18.05.30.5.2m-placement-of-shares-to-Fidelity-International-thumb.jpg2018-11-05T09:25:15.000Z"95328d66d205a4b853dcfc6f253162c1"14803STANDARD348/18.05.31.Cynatas-MSCs-Effective-in-Model-of-Diabetic-Wounds.pdf2018-11-04T23:52:52.000Z"9ac429cc718a72d0bb1e29616534a654"189890STANDARD348/conversions/18.05.31.Cynatas-MSCs-Effective-in-Model-of-Diabetic-Wounds-thumb.jpg2018-11-05T09:25:15.000Z"e5f09125f4d16e7fb964bfbd8d2fb1c8"17562STANDARD349/18.06.04.Appendix-3B.pdf2018-11-04T23:52:52.000Z"4ca14b845a074a3c97d9f025859027b3"193690STANDARD349/conversions/18.06.04.Appendix-3B-thumb.jpg2018-11-05T09:25:16.000Z"83361aacdcd258c827d76f782f6cd6e2"11834STANDARD35/conversions/f0edb.13.08.23.Section708ANot-thumb.jpg2018-11-06T05:47:39.000Z"394b692573f9135a59963c7100f2cc4d"13259STANDARD35/f0edb.13.08.23.Section708ANot.pdf2018-11-04T23:51:25.000Z"beb5b86e2cf24b8a96056d31a0c8029c"85561STANDARD350/18.06.04.Cleansing-Notice.pdf2018-11-04T23:52:52.000Z"54fb6e839c63ca700f6e1dcea9bc25e7"104894STANDARD350/conversions/18.06.04.Cleansing-Notice-thumb.jpg2018-11-05T09:25:17.000Z"ec0b2201a436df8dca3b528cac70f8b1"10630STANDARD351/18.06.12.Positive-6-Month-Data-from-Cohort-A-in-Phase-1-Trial-in-GvHD.pdf2018-11-04T23:52:52.000Z"5484254a1b9ab1c4342867ff88d9c492"182697STANDARD351/conversions/18.06.12.Positive-6-Month-Data-from-Cohort-A-in-Phase-1-Trial-in-GvHD-thumb.jpg2018-11-05T09:25:18.000Z"3f80fad661597233fb43777a8dd2f121"17314STANDARD352/18.06.18.Research-Collaboration-with-UNSW-for-Coronary-Artery-Disease.pdf2018-11-04T23:52:52.000Z"2b957e1cc3b5ffcbfd710aa55b95534e"175063STANDARD352/conversions/18.06.18.Research-Collaboration-with-UNSW-for-Coronary-Artery-Disease-thumb.jpg2018-11-05T09:25:19.000Z"1cabfa5090b3db1f4376974f121ea3e4"18227STANDARD353/18.06.21.Positive-28-day-Clinical-Trial-Data-in-Cohort-B.pdf2018-11-04T23:52:52.000Z"cec1c1d8309f96049defdc946f92d499"220933STANDARD353/conversions/18.06.21.Positive-28-day-Clinical-Trial-Data-in-Cohort-B-thumb.jpg2018-11-05T09:25:20.000Z"db820bf118453d1eec66b05461da81bb"17174STANDARD354/18.06.26.Product-Development-Program-Update-Investor-Presentation.pdf2018-11-04T23:52:53.000Z"d32a3f1cc678c3a3756f7a24a917fffc"2017756STANDARD354/conversions/18.06.26.Product-Development-Program-Update-Investor-Presentation-thumb.jpg2018-11-05T09:25:22.000Z"bbc7f834a49f0771403d07a756a67865"18180STANDARD355/180625-Cynata-investor-presentation-vFF_kk2.pdf2018-11-04T23:52:54.000Z"bca1a5f353ec986d2ad6d7e6ce4778ae"2110100STANDARD355/conversions/180625-Cynata-investor-presentation-vFF_kk2-thumb.jpg2018-11-05T09:25:23.000Z"eb630c53dc6c900a94819a53d345dd5f"11249STANDARD356/18.07.02.Cynata-Enters-Development-Partnership-with-RCSI.pdf2018-11-04T23:52:54.000Z"095591ee926d6690a35dda03b70aa856"216381STANDARD356/conversions/18.07.02.Cynata-Enters-Development-Partnership-with-RCSI-thumb.jpg2018-11-05T09:25:24.000Z"abddce095f362837634fbff1006edcd2"18583STANDARD357/18.07.06.Appendix-3B.pdf2018-11-04T23:52:55.000Z"19ac3cfcf3a93b5c5b3c9b012bdf3bcc"193326STANDARD357/conversions/18.07.06.Appendix-3B-thumb.jpg2018-11-05T09:25:25.000Z"0984d69a3f2a4426d596b774c0f4e5a3"11838STANDARD358/18.07.06.Cleansing-Notice.pdf2018-11-04T23:52:55.000Z"513bb1ae9662e39b4b76d3a4d5bc74b5"104421STANDARD358/conversions/18.07.06.Cleansing-Notice-thumb.jpg2018-11-05T09:25:25.000Z"db6ebbf29e0fbac55506fcc2a259e746"10524STANDARD359/18.07.11.June-2018-Quarterly-Report.pdf2018-11-04T23:52:55.000Z"ec2545e0eb47b7e7457ff9a6f859bf27"318567STANDARD359/conversions/18.07.11.June-2018-Quarterly-Report-thumb.jpg2018-11-05T09:25:26.000Z"10c59df64878a415c39e4ff38a143064"16211STANDARD36/87da9.13.08.23.DetailsofCompa.pdf2018-11-04T23:51:25.000Z"b09a1c8bba732ec3fe507102322b1614"166928STANDARD36/conversions/87da9.13.08.23.DetailsofCompa-thumb.jpg2018-11-06T05:47:40.000Z"1eb32ec5e68489cdb60f95c1cbed277a"8159STANDARD360/18.07.11.Appendix-3B.pdf2018-11-04T23:52:55.000Z"bed69c857d9ab4dd8b83545895267aa6"194050STANDARD360/conversions/18.07.11.Appendix-3B-thumb.jpg2018-11-05T09:25:27.000Z"f821298295f2fb78d8dab7b03bab06f2"11837STANDARD361/18.07.11.Cleansing-Notice.pdf2018-11-04T23:52:56.000Z"2a4257b2dabde1509b87a196fc493157"104233STANDARD361/conversions/18.07.11.Cleansing-Notice-thumb.jpg2018-11-05T09:25:28.000Z"23cca282f91fa7c7b694123cc4e7936c"10316STANDARD362/18.07.16.Appendix-3B.pdf2018-11-04T23:52:56.000Z"af034c089fba9c920886d97fdfd5f50d"194291STANDARD362/conversions/18.07.16.Appendix-3B-thumb.jpg2018-11-05T09:25:28.000Z"4bef137671bd3a9e2bb0725e41da527e"11842STANDARD363/18.07.16.Cleansing-Notice.pdf2018-11-04T23:52:56.000Z"d3dba04fc97181c60aec33eebfd9a777"104660STANDARD363/conversions/18.07.16.Cleansing-Notice-thumb.jpg2018-11-05T09:25:29.000Z"6ef91dd34f29a5b5ffeb7b44cd8aec23"10508STANDARD364/18.07.31.Cymerus-MSCs-improve-cardiac-recovery-in-preclinical-study.pdf2018-11-04T23:52:56.000Z"39f23a5cccddad95001a57283cb36df3"208716STANDARD364/conversions/18.07.31.Cymerus-MSCs-improve-cardiac-recovery-in-preclinical-study-thumb.jpg2018-11-05T09:25:30.000Z"13c054882bf09255d42ffbb36a245f5d"17996STANDARD365/18.08.10.Notice-of-General-Meeting-and-Proxy-Form.pdf2018-11-04T23:52:57.000Z"8f89ced97c7e347f93e9d59db9e664f3"941868STANDARD365/conversions/18.08.10.Notice-of-General-Meeting-and-Proxy-Form-thumb.jpg2018-11-05T09:25:31.000Z"813d6c3cbf4585286c23b142fa742847"16377STANDARD366/18.08.22.Appendix-4E-Financial-Statements.pdf2018-11-04T23:52:57.000Z"9015ba2824b030f9ed45a66643d7fb1e"1111412STANDARD366/conversions/18.08.22.Appendix-4E-Financial-Statements-thumb.jpg2018-11-05T09:25:32.000Z"2ffcea9166fb0794cd761a120e3d8617"14029STANDARD367/2018-Appendix-4G.pdf2018-11-04T23:52:57.000Z"214a6b9234a49fb5e29808a2566dd810"153763STANDARD367/conversions/2018-Appendix-4G-thumb.jpg2018-11-05T09:25:33.000Z"82248e3e15774dc89b94676d3e2a78bb"3540STANDARD368/18.08.24.Updated-Appendix-4G.pdf2018-11-04T23:52:58.000Z"b434476658c86515e63761f8d95fa982"234367STANDARD368/conversions/18.08.24.Updated-Appendix-4G-thumb.jpg2018-11-05T09:25:33.000Z"2d6c8b115e9ba83633dba045e5bd36f3"3580STANDARD369/18.08.30.Cynata-GvHD-Trial-Meets-all-Safety-and-Efficacy-Endpoints.pdf2018-11-04T23:52:58.000Z"58b80db99804406c750970607ca4b820"244364STANDARD369/conversions/18.08.30.Cynata-GvHD-Trial-Meets-all-Safety-and-Efficacy-Endpoints-thumb.jpg2018-11-05T09:25:35.000Z"aa154ab9e2d0d23c2d53cb9e6ebc36d6"17473STANDARD37/conversions/d94c9.13.08.19.Section708ANot-thumb.jpg2018-11-06T05:47:41.000Z"0c51edf1f5e4bbc8824d204100219e11"13303STANDARD37/d94c9.13.08.19.Section708ANot.pdf2018-11-04T23:51:25.000Z"67a68cf593ca6ce18d2e115575c310e5"85690STANDARD370/18.08.31.Cynata-to-Present-at-Rodman-Renshaw-Investor-Conference.pdf2018-11-04T23:52:58.000Z"bb6369d7922a86d2b015c81986868aca"1653273STANDARD370/conversions/18.08.31.Cynata-to-Present-at-Rodman-Renshaw-Investor-Conference-thumb.jpg2018-11-05T09:25:36.000Z"4c2396c1fb76f930f7f3936f5b649931"14950STANDARD371/18.09.03.Cynata-Advances-to-Official-Meeting-with-Japanese-PDMA.pdf2018-11-04T23:52:59.000Z"f8067ea2886fe8f7058aac07675a54ce"174182STANDARD371/conversions/18.09.03.Cynata-Advances-to-Official-Meeting-with-Japanese-PDMA-thumb.jpg2018-11-05T09:25:37.000Z"91de979478e6618fb94f4cf8091c5a08"16444STANDARD372/18.09.04.Director-Loan-Funded-Shares-Voluntary-Escrow-Arrangement.pdf2018-11-04T23:52:59.000Z"d71e2cece3e1b04d86d5255c164b2404"165127STANDARD372/conversions/18.09.04.Director-Loan-Funded-Shares-Voluntary-Escrow-Arrangement-thumb.jpg2018-11-05T09:25:38.000Z"5a94b96ff71a635b11cd5122941e56e8"15393STANDARD373/18.09.12.Results-of-General-Meeting.pdf2018-11-04T23:52:59.000Z"ee3156e5d0d488f92e88cb8b9f80541e"197102STANDARD373/conversions/18.09.12.Results-of-General-Meeting-thumb.jpg2018-11-05T09:25:38.000Z"7596f0281221f397960d581fa9d43759"7981STANDARD374/18.09.19.Cynata-MSCs-Ameliorate-CRS-in-Preclinical-Study.pdf2018-11-04T23:53:00.000Z"d9fdb825e3c414a45434d2fb460c437a"207168STANDARD374/conversions/18.09.19.Cynata-MSCs-Ameliorate-CRS-in-Preclinical-Study-thumb.jpg2018-11-05T09:25:39.000Z"499895d89ac4f823f0eff6994797e333"16049STANDARD375/18.09.25.Appendix-3B.pdf2018-11-04T23:53:00.000Z"4891bcba1a894931ee1e6181cc41ebb2"195501STANDARD375/conversions/18.09.25.Appendix-3B-thumb.jpg2018-11-05T09:25:40.000Z"20b9bdb2875020900b079596cb632903"12339STANDARD376/18.09.25.Cleansing-Notice.pdf2018-11-04T23:53:00.000Z"a93690689aa29cc6bb0e491c4cbb6dc6"111322STANDARD376/conversions/18.09.25.Cleansing-Notice-thumb.jpg2018-11-05T09:25:41.000Z"8e65305ff05259758d1df935c6f550b1"12231STANDARD377/18.09.25.Appendix-3Y-Paul-Wotton.pdf2018-11-04T23:53:00.000Z"5929e814ac7b032530f5dcd23123dcfb"26329STANDARD377/conversions/18.09.25.Appendix-3Y-Paul-Wotton-thumb.jpg2018-11-05T09:25:41.000Z"98b02c1db5921e0a035c62d8bed11a04"13681STANDARD378/18.09.25.Appendix-3Y-Ross-Macdonald.pdf2018-11-04T23:53:00.000Z"5621f9661155ce4c2b700cab2ffe6f1f"26722STANDARD378/conversions/18.09.25.Appendix-3Y-Ross-Macdonald-thumb.jpg2018-11-05T09:25:42.000Z"bcdebcd5c29fe2562668883e4bd79eab"14340STANDARD379/18.09.25.Appendix-3Y-Stewart-Washer.pdf2018-11-04T23:53:00.000Z"3b64f880d32386510ecdc3a00f4c39e7"26221STANDARD379/conversions/18.09.25.Appendix-3Y-Stewart-Washer-thumb.jpg2018-11-05T09:25:43.000Z"2279573328abc139f24729085103d27a"14996STANDARD38/39adc.13.08.16.Appendix3B-Exer.pdf2018-11-04T23:51:26.000Z"a433363ad32c3979ecefed3e277928f6"127941STANDARD38/conversions/39adc.13.08.16.Appendix3B-Exer-thumb.jpg2018-11-06T05:47:41.000Z"0162b8614ca0955244f0f5621efa27cc"10485STANDARD380/18.09.27.Notification-of-2018-Annual-General-Meeting-Date.pdf2018-11-04T23:53:00.000Z"17d028e737a87cdea0b714800d318b1c"164365STANDARD380/conversions/18.09.27.Notification-of-2018-Annual-General-Meeting-Date-thumb.jpg2018-11-05T09:25:43.000Z"7f0a029c0504e5e87bc89d32b31f3651"11141STANDARD381/18.10.11.Notice-of-AGMProxy-Form.pdf2018-11-04T23:53:01.000Z"8d5092cef0f82f7de2bd9a7182208f16"903107STANDARD381/conversions/18.10.11.Notice-of-AGMProxy-Form-thumb.jpg2018-11-05T09:25:44.000Z"d0dde9594d8cab0a3de4a83094ccea53"8187STANDARD382/18.10.11.Annual-Report-to-Shareholders.pdf2018-11-04T23:53:01.000Z"53ca7ae12d7c885fbe10accdd599da40"1122552STANDARD382/conversions/18.10.11.Annual-Report-to-Shareholders-thumb.jpg2018-11-05T09:25:45.000Z"24120740ba2ae4fd95c7ab13efe65720"4454STANDARD383/18.07.11.June-2018-Quarterly-Report1.pdf2018-11-04T23:53:02.000Z"189c159441dcd9c1ea271d779a9bac9a"318399STANDARD383/conversions/18.07.11.June-2018-Quarterly-Report1-thumb.jpg2018-11-05T09:25:46.000Z"10c59df64878a415c39e4ff38a143064"16211STANDARD384/18.08.22.Appendix-4E-Financial-Statements1.pdf2018-11-04T23:53:02.000Z"dd647a2fa667e24cec0ac4ba3b438ac6"1124240STANDARD384/conversions/18.08.22.Appendix-4E-Financial-Statements1-thumb.jpg2018-11-05T09:25:47.000Z"2ffcea9166fb0794cd761a120e3d8617"14029STANDARD385/18.10.11.Annual-Report-to-Shareholders-1.pdf2018-11-04T23:53:03.000Z"53ca7ae12d7c885fbe10accdd599da40"1122552STANDARD385/conversions/18.10.11.Annual-Report-to-Shareholders-1-thumb.jpg2018-11-05T09:25:48.000Z"24120740ba2ae4fd95c7ab13efe65720"4454STANDARD386/18.10.18.MSCs-Demonstrate-Anti-Cancer-Effects-in-Pre-Clinical-Studies.pdf2018-11-04T23:53:03.000Z"58f8280582052aa8b2acf4544dca61c5"205588STANDARD386/conversions/18.10.18.MSCs-Demonstrate-Anti-Cancer-Effects-in-Pre-Clinical-Studies-thumb.jpg2018-11-05T09:25:49.000Z"a6214a33e36e3371b6b56d3484fdb7a9"16474STANDARD387/18.10.23.September-2018-Quarterly-Report.pdf2018-11-04T23:53:04.000Z"c046f75397615d7ab8de10b2b3ec13c5"359339STANDARD387/conversions/18.10.23.September-2018-Quarterly-Report-thumb.jpg2018-11-05T09:25:50.000Z"49e0201e7f6a4d0cc8e67c2f4013a10b"15346STANDARD388/18.10.23.September-2018-Quarterly-Report-1.pdf2018-11-04T23:53:04.000Z"c046f75397615d7ab8de10b2b3ec13c5"359339STANDARD388/conversions/18.10.23.September-2018-Quarterly-Report-1-thumb.jpg2018-11-05T09:25:50.000Z"49e0201e7f6a4d0cc8e67c2f4013a10b"15346STANDARD389/18.10.26.Appendix-3Y-Paul-Wotton.pdf2018-11-04T23:53:04.000Z"d69243e785f32e083d1bafc8135bcaef"25955STANDARD389/conversions/18.10.26.Appendix-3Y-Paul-Wotton-thumb.jpg2018-11-05T09:25:51.000Z"24a2e087d723468fcdf3c59950e6581e"13182STANDARD39/1a523.13.08.15.ResponsetoASX.pdf2018-11-04T23:51:26.000Z"bd2b84a70c4e80242a239e6fba5f0ba8"85079STANDARD39/conversions/1a523.13.08.15.ResponsetoASX-thumb.jpg2018-11-06T05:47:42.000Z"4016928efd65b20a724597d51538573c"15496STANDARD390/18.11.01.Cynata-Outlook-and-Investor-Presentation.pdf2018-11-04T23:53:04.000Z"46b71f730517faeba81dc4b714dd5a6e"2146525STANDARD391/18.11.02.Cynata-Clinical-Trial-Data-Accepted-for-presentation-at-ASH.pdf2018-11-04T23:53:05.000Z"2b7923e30c96c2d3595bbe08425b953f"177221STANDARD391/conversions/18.11.02.Cynata-Clinical-Trial-Data-Accepted-for-presentation-at-ASH-thumb.jpg2018-11-05T09:25:53.000Z"3971316213c4ec9845a2ce21a8738998"15741STANDARD392/Cynata-Therapeutics-CYP-AU_04Mar16-Update.pdf2018-11-05T03:39:17.000Z"7bcc106d47f1535df1e911f42fe1d496"172019STANDARD392/conversions/Cynata-Therapeutics-CYP-AU_04Mar16-Update-thumb.jpg2018-11-05T09:25:54.000Z"ad7d28e1d7da2995733131ca5de42494"22267STANDARD393/FNB_DV_20160510_d51cc18bc6af4391904aa5e08a44dd5d.pdf2018-11-05T03:41:43.000Z"39a29e6b36204b62900370ff70173bd8"325902STANDARD393/conversions/FNB_DV_20160510_d51cc18bc6af4391904aa5e08a44dd5d-thumb.jpg2018-11-05T09:25:55.000Z"59bbc79ec1ce29961554d9d962c3a814"20826STANDARD394/conversions/f9e6cca7-3a05-4e4b-a664-e48bbc5e06fb-2-thumb.jpg2018-11-05T09:25:56.000Z"7ad692e97d90fadf46826126f388deb9"22533STANDARD394/f9e6cca7-3a05-4e4b-a664-e48bbc5e06fb-2.pdf2018-11-05T03:43:12.000Z"a541ded1264b443036ccb455db9151b9"236630STANDARD395/CYP-Desk-Note-23032016.pdf2018-11-05T03:47:16.000Z"22beefd12736579a5bb2f4b9c3b2af54"983279STANDARD395/conversions/CYP-Desk-Note-23032016-thumb.jpg2018-11-05T09:25:57.000Z"774356afbf2b104a679dc7f244b4fe50"13601STANDARD396/CYNATA-DESK-NOTE-AUGUST-2016-UPDATE.pdf2018-11-05T03:49:41.000Z"4319b38c80a2368d0b8afd3c63c2d16f"319504STANDARD396/conversions/CYNATA-DESK-NOTE-AUGUST-2016-UPDATE-thumb.jpg2018-11-05T09:25:58.000Z"5ee3bd4b7d608f1910582147de6d368c"10408STANDARD397/1590817.pdf2018-11-05T03:50:35.000Z"adca1e5e9c224f09b32f2640c4c8f772"170701STANDARD397/conversions/1590817-thumb.jpg2018-11-05T09:25:59.000Z"7b34042afe7aff1212cf420b7a690ea0"15730STANDARD398/Shaws-Flash-Note-Fujifilm-06Sept16.pdf2018-11-05T03:53:16.000Z"cd635d23a5c740d1844a23edcdc8c1b1"553658STANDARD398/conversions/Shaws-Flash-Note-Fujifilm-06Sept16-thumb.jpg2018-11-05T09:26:00.000Z"52035f6e52c2906edc6fe1cf5e30b039"19730STANDARD399/16.09.19.UK-Regulatory-Authority-Approves-GvHD-Clinical-Trial.pdf2018-11-05T03:55:10.000Z"00d439adb03c607a0cfc507df77fa853"223052STANDARD399/conversions/16.09.19.UK-Regulatory-Authority-Approves-GvHD-Clinical-Trial-thumb.jpg2018-11-05T09:26:01.000Z"8ffc79d6cc241189d5e5b20515c8610d"17890STANDARD4/6e34b.CynataTherapeuticsCYP-.pdf2018-11-04T11:27:12.000Z"3051d3988e23cfd0a37492db171c94eb"1017728STANDARD4/conversions/6e34b.CynataTherapeuticsCYP--thumb.jpg2018-11-06T05:47:15.000Z"46ea7d1aa81c56abaa52af20c049c896"20039STANDARD40/conversions/de090.13.08.13.SPPOfferDocume-thumb.jpg2018-11-06T05:47:43.000Z"741c258e6b8b5d62489c0d7421f0e275"15487STANDARD40/de090.13.08.13.SPPOfferDocume.pdf2018-11-04T23:51:26.000Z"81a5ce1412d83bf1cf9ab0ac80ed5035"260872STANDARD400/The-Australian-11.10.2016.pdf2018-11-05T03:56:18.000Z"385f291c1a622a75873d36da403721b7"342913STANDARD400/conversions/The-Australian-11.10.2016-thumb.jpg2018-11-05T09:26:02.000Z"a07cb531d1ec9dfab3550f626b4b79ed"16931STANDARD401/FNB_DV_20170221_7c2737884c374bd2987afd69e13e23e7.pdf2018-11-05T03:59:35.000Z"8f45632befb4c4d8b3036f69556c7d76"335170STANDARD401/conversions/FNB_DV_20170221_7c2737884c374bd2987afd69e13e23e7-thumb.jpg2018-11-05T09:26:03.000Z"c8ad2a85d4c541057d5bd8a0c25a5398"21179STANDARD402/CR_DV_CYP_20170505_408b16c568034b13963b09ec14685e5f.pdf2018-11-05T04:47:26.000Z"a08cc6a3e16eb9819947b51e8ff35c83"648956STANDARD402/conversions/CR_DV_CYP_20170505_408b16c568034b13963b09ec14685e5f-thumb.jpg2018-11-05T09:26:04.000Z"f317e604bed47d71a40efa836d99aad2"21764STANDARD403/RESEARCH-NOTE-CYNATA-1-JUNE-2017.pdf2018-11-05T04:52:37.000Z"55d7d331e9c1e9cae307afee7a2d96db"1162642STANDARD403/conversions/RESEARCH-NOTE-CYNATA-1-JUNE-2017-thumb.jpg2018-11-05T09:26:05.000Z"75f74358434a584335099fcd9e0b76c5"8990STANDARD404/2017-07-24b-Cynata-report-from-NDF-Research.pdf2018-11-05T04:56:16.000Z"f9ee870f8ea5bc5ef72632dc51bc4d34"1652365STANDARD404/conversions/2017-07-24b-Cynata-report-from-NDF-Research-thumb.jpg2018-11-05T09:26:06.000Z"206c89cd7278a5a5363c278d23bf45e9"14786STANDARD405/Cynata-Investor-Presentation-Rodman-Renshaw-Sept-2017-CYP-website-1.pdf2018-11-05T04:57:18.000Z"c8be22c3a0db2d21eca4079df85ca4f1"966626STANDARD405/conversions/Cynata-Investor-Presentation-Rodman-Renshaw-Sept-2017-CYP-website-1-thumb.jpg2018-11-05T09:26:07.000Z"12f0985e5683b751b54f1cdedd8a77c5"13021STANDARD406/Cynata-Therapeutics-CYP-AU_08Sep17-Update.pdf2018-11-05T04:58:09.000Z"101849cf6f83f4b58baee8bf2fc86245"455927STANDARD406/conversions/Cynata-Therapeutics-CYP-AU_08Sep17-Update-thumb.jpg2018-11-05T09:26:08.000Z"16e5b9505de44342ad67c11b095f7b71"25117STANDARD407/RESEARCH-NOTE-CYNATA-9-October-2017.pdf2018-11-05T04:59:47.000Z"6df449c9d0e1128e7be027f1e7a7bd01"1403694STANDARD407/conversions/RESEARCH-NOTE-CYNATA-9-October-2017-thumb.jpg2018-11-05T09:26:09.000Z"72b8d8176273b287e7e1e6a78f4bcbfe"9166STANDARD408/Cynata-Therapeutics-CYP-AU_20Nov17-Update.pdf2018-11-05T05:02:31.000Z"812146380b593f01364072ebd74efd26"422378STANDARD408/conversions/Cynata-Therapeutics-CYP-AU_20Nov17-Update-thumb.jpg2018-11-05T09:26:10.000Z"f8c399d8579ca37ac80756ef5feb39ad"19895STANDARD409/17.12.xx-Japan-investor-meetings-v09.pdf2018-11-05T05:03:31.000Z"f3ce0e3c3b78dad258d3797a67b5af82"1065013STANDARD409/conversions/17.12.xx-Japan-investor-meetings-v09-thumb.jpg2018-11-05T09:26:11.000Z"0360d992e684a005fe5e22b846abad86"15696STANDARD41/ba8c7.13.08.07Appendix3B.pdf2018-11-04T23:51:26.000Z"9055dc6b5ff8b234d64041aa0660ebce"128886STANDARD41/conversions/ba8c7.13.08.07Appendix3B-thumb.jpg2018-11-06T05:47:44.000Z"b23fb0b5836aac5ebb83d2c525dcdaf3"4885STANDARD410/Cynata-Therapeutics-CYP-AU_22Jan18-Update.pdf2018-11-05T05:04:07.000Z"25400df2896f3725330b0f0beddf99f3"440674STANDARD410/conversions/Cynata-Therapeutics-CYP-AU_22Jan18-Update-thumb.jpg2018-11-05T09:26:12.000Z"96e5f2dfc118558ff185ed8f8befa448"20260STANDARD411/Shaws-Flash-Note-23Jan18.pdf2018-11-05T05:04:47.000Z"f3ef63f4f75df8ece3ff99e2b33a79b8"364888STANDARD411/conversions/Shaws-Flash-Note-23Jan18-thumb.jpg2018-11-05T09:26:14.000Z"391836ea8d7cd62ee87e4afc4174b693"18109STANDARD412/Cynata-Therapeutics-CYP-AU_28Feb18-Update.pdf2018-11-05T05:05:23.000Z"bc1a60d4af5ba53acd677758f84b3d80"443077STANDARD412/conversions/Cynata-Therapeutics-CYP-AU_28Feb18-Update-thumb.jpg2018-11-05T09:26:15.000Z"f4869ed38e1e47e2141ef257efe3f55e"24972STANDARD413/CR_DV_CYP_20180311_8ad5aea26acc4911a9b17f9923f7d3a7.pdf2018-11-05T05:05:54.000Z"5ee15bf1b6fa21ceb3b883f61d5b955d"380503STANDARD413/conversions/CR_DV_CYP_20180311_8ad5aea26acc4911a9b17f9923f7d3a7-thumb.jpg2018-11-05T09:26:16.000Z"f3024964618e84ae639fe3cd9bb23267"19977STANDARD414/Cynata-Therapeutics-CYP-AU_02Apr18-Update.pdf2018-11-05T05:06:32.000Z"4b5a4fb7b4cece9b5b996333a52c3901"441263STANDARD414/conversions/Cynata-Therapeutics-CYP-AU_02Apr18-Update-thumb.jpg2018-11-05T09:26:17.000Z"285b212dac50155f91a2f0720390c586"20932STANDARD415/2018-06-22a-Cynata-update-report-from-NDF-Research.pdf2018-11-05T05:08:06.000Z"a62db745f8a614c0327b1afc3226f2d4"462873STANDARD415/conversions/2018-06-22a-Cynata-update-report-from-NDF-Research-thumb.jpg2018-11-05T09:26:18.000Z"b7008aef3acc9b62a9dacb55595744ad"8747STANDARD416/FN_DV_CYP_20180622_2a27fda67a464408965ad71c00be8ba8.pdf2018-11-05T05:09:34.000Z"e3e279283ce4b6ec9d7c6819e7b8539c"365032STANDARD416/conversions/FN_DV_CYP_20180622_2a27fda67a464408965ad71c00be8ba8-thumb.jpg2018-11-05T09:26:19.000Z"e480ad711f9b7fe12f0c8b82c727f713"20864STANDARD417/Cynata-Therapeutics-CYP-AU_17Sept18-Update.pdf2018-11-05T05:13:36.000Z"44d22ff0109baee18b668b5e6fb77f47"418828STANDARD417/conversions/Cynata-Therapeutics-CYP-AU_17Sept18-Update-thumb.jpg2018-11-05T09:26:21.000Z"2587aca8f63f5780e705e005f333db7e"24959STANDARD42/conversions/eb5b1.13.11.14.Consolidationof-thumb.jpg2018-11-06T05:47:45.000Z"640464caeee5018ed77b0b803d257e1e"5049STANDARD42/eb5b1.13.11.14.Consolidationof.pdf2018-11-04T23:51:26.000Z"1eca40eb072c0c35a5d7802f19731aa5"87492STANDARD420/FN_DV_CYP_20180622_2a27fda67a464408965ad71c00be8ba8.pdf2018-11-06T05:12:57.000Z"e3e279283ce4b6ec9d7c6819e7b8539c"365032STANDARD428/17.06.22.CYP-MSC-Data-in-Asthma-Model-Published-in-Scientific-Journal.pdf2018-11-06T05:46:28.000Z"f7f36aa531924dd52196e08241471dc7"235857STANDARD428/conversions/17.06.22.CYP-MSC-Data-in-Asthma-Model-Published-in-Scientific-Journal-thumb.jpg2018-11-06T05:50:07.000Z"3fd3f01f47b1962accd1dcd7385f0a85"18132STANDARD43/8bbf7.13.11.14.Appendix3Y-Stew.pdf2018-11-04T23:51:26.000Z"0e283bb97965756a387871854a997a12"22932STANDARD43/conversions/8bbf7.13.11.14.Appendix3Y-Stew-thumb.jpg2018-11-06T05:47:46.000Z"69a49756427486483de7bea283e1ef50"13032STANDARD436/18.11.07.CYP-Receives-Notice-of-Allowance-from-European-Patent-Office.pdf2018-11-06T23:39:02.000Z"29c5bc5cd69cef00db8c9ccd9c249c3a"190003STANDARD436/conversions/18.11.07.CYP-Receives-Notice-of-Allowance-from-European-Patent-Office-thumb.jpg2018-11-06T23:39:04.000Z"715f5cb1e99066774e386c03d6427ee7"14312STANDARD437/2018-11-08T21:39:40.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARD437/16.09.19.UK-Regulatory-Authority-Approves-GvHD-Clinical-Trial.pdf2018-11-08T21:39:40.000Z"00d439adb03c607a0cfc507df77fa853"223052STANDARD437/18.11.01.Cynata-Outlook-and-Investor-Presentation.pdf2018-11-08T21:40:44.000Z"46b71f730517faeba81dc4b714dd5a6e"2146525STANDARD437/conversions/2018-11-08T21:39:41.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARD437/conversions/16.09.19.UK-Regulatory-Authority-Approves-GvHD-Clinical-Trial-thumb.jpg2018-11-08T21:39:41.000Z"8ffc79d6cc241189d5e5b20515c8610d"17890STANDARD437/conversions/18.11.01.Cynata-Outlook-and-Investor-Presentation-thumb.jpg2018-11-08T21:41:04.000Z"4ce924bb1e125c80023d7f6689dc7868"12392STANDARD438/18.11.15.Annual-General-Meeting-Presentation.pdf2018-11-15T00:29:31.000Z"beb412a7dfc834c951a21a43461ecfa4"1847053STANDARD438/conversions/18.11.15.Annual-General-Meeting-Presentation-thumb.jpg2018-11-15T00:29:40.000Z"948a317eb097546222446a52f2a1fe2b"12593STANDARD439/18.11.15.Chairman's-AGM-Address.pdf2018-11-15T00:31:48.000Z"d51b88169297f2facf6cd02532ae3fb0"140681STANDARD439/conversions/18.11.15.Chairman's-AGM-Address-thumb.jpg2018-11-15T00:31:49.000Z"12f351dd83b12738a4c66b2d261c0422"17391STANDARD44/ccba8.13.11.04.ECQRaises5MT.pdf2018-11-04T23:51:26.000Z"0b83c46c12bfa67332e04a175760a363"85786STANDARD44/conversions/ccba8.13.11.04.ECQRaises5MT-thumb.jpg2018-11-06T05:47:47.000Z"ce8355fa83cc09754e7a23b4337c0bf6"5140STANDARD440/18.11.15.Results-of-Annual-General-Meeting.pdf2018-11-15T04:52:31.000Z"6cc56617c70110cf4b1b46b30d422afb"198216STANDARD441/18.11.15.Replacement-Results-of-Annual-General-Meeting.pdf2018-11-15T04:54:32.000Z"90394fc3c4ea76509a1cb938dada1ae5"186485STANDARD442/18.11.15.Annual-General-Meeting-Presentation.pdf2018-11-15T05:01:17.000Z"beb412a7dfc834c951a21a43461ecfa4"1847053STANDARD442/conversions/18.11.15.Annual-General-Meeting-Presentation-thumb.jpg2018-11-15T05:01:25.000Z"948a317eb097546222446a52f2a1fe2b"12593STANDARD443/18.11.19.Cynata-receives-$1.3m-R&D-Tax-Incentive-Refund.pdf2018-11-18T22:36:59.000Z"8e2f59572402134df0da9a935867c431"167823STANDARD443/conversions/18.11.19.Cynata-receives-$1.3m-R&D-Tax-Incentive-Refund-thumb.jpg2018-11-18T22:37:00.000Z"f6ef2f67bc606ffb00c35a4e18c4eac6"11132STANDARD444/18.12.13.NHMRC-Funding-for-Osteroarthritis-Trial-Using-Cymerus-MSCs.pdf2018-12-12T22:33:10.000Z"c64bd21daafe91dd414606dba36ccdb2"216991STANDARD444/conversions/18.12.13.NHMRC-Funding-for-Osteroarthritis-Trial-Using-Cymerus-MSCs-thumb.jpg2018-12-12T22:33:12.000Z"ea04c53b8d7eaa0443dcb6fba029b46f"15862STANDARD445/Cynata-Therapeutics-(CYP-AU)_14Dec18-Update.pdf2018-12-17T09:57:00.000Z"0185ffec6cc0c31b9b6e12a2ec102d1f"429151STANDARD445/conversions/Cynata-Therapeutics-(CYP-AU)_14Dec18-Update-thumb.jpg2018-12-17T09:57:02.000Z"22102dd656ed61d131edc7a86b8b4bec"20901STANDARD446/18.12.18.Cynata-Completes-Clinical-Study-Report-in-GvHD.pdf2018-12-17T22:28:14.000Z"d3a211d2025044bcae30e6c139aff4cd"186118STANDARD446/conversions/18.12.18.Cynata-Completes-Clinical-Study-Report-in-GvHD-thumb.jpg2018-12-17T22:28:15.000Z"fd1c2e0736ace8703fee1d8c01cb8dcb"15333STANDARD447/18.12.20.End-of-Year-Newsletter.pdf2018-12-20T01:40:41.000Z"9b5a430a56b223bd39784c5e3f16aff6"355005STANDARD447/conversions/18.12.20.End-of-Year-Newsletter-thumb.jpg2018-12-20T01:40:44.000Z"c7855a8d44e8408faa06d2ad8b0ae5d3"9008STANDARD45/451a9.13.10.29.ResultsofAnnua.pdf2018-11-04T23:51:26.000Z"21f76390b62c06b7e7f0ee161278d1b2"107712STANDARD45/conversions/451a9.13.10.29.ResultsofAnnua-thumb.jpg2018-11-06T05:47:48.000Z"4f480c3f2bf66a5b535cdf678e3a111a"3711STANDARD46/conversions/fc42f.13.10.29.CEOPresentation-thumb.jpg2018-11-06T05:47:49.000Z"f3b72bd41e57d4446f3e70a60ca7a2b8"18300STANDARD46/fc42f.13.10.29.CEOPresentation.pdf2018-11-04T23:51:27.000Z"52e54a47698a6d2c04226780bd54011c"1158395STANDARD47/8bb1e.13.10.29.Appendix4C.pdf2018-11-04T23:51:28.000Z"a1efaa894bf145810d27aa2179c8cb9e"453266STANDARD47/conversions/8bb1e.13.10.29.Appendix4C-thumb.jpg2018-11-06T05:47:50.000Z"54a3e503b0ea921ae3ca54870655f224"10221STANDARD48/21368.13.10.28.Suspensionfrom.pdf2018-11-04T23:51:29.000Z"be9568ea40e2d7e49eefc7b22ee0a56d"276768STANDARD48/conversions/21368.13.10.28.Suspensionfrom-thumb.jpg2018-11-06T05:47:50.000Z"d9ce6b4e875a6e27b49f52be056a02d2"6905STANDARD49/9ca56.13.10.28.EcoQuestExecut.pdf2018-11-04T23:51:29.000Z"ce3e6865c7fc7284a8d4adc8da383efb"70989STANDARD49/conversions/9ca56.13.10.28.EcoQuestExecut-thumb.jpg2018-11-06T05:47:52.000Z"80cbc3604d828718642cb9e84e3dbd26"5254STANDARD5/12c60.CYYNFInitiationReport..pdf2018-11-04T11:33:39.000Z"97f91ef40afe3aff53061d07732cc8fc"991274STANDARD5/conversions/12c60.CYYNFInitiationReport.-thumb.jpg2018-11-06T05:47:16.000Z"41119047282ba0c80cfe4bf84e547fcf"8870STANDARD50/2aafc.13.10.04.ReplacementAppe.pdf2018-11-04T23:51:29.000Z"72a222abc443b76e56a62def23c58b8f"171496STANDARD50/conversions/2aafc.13.10.04.ReplacementAppe-thumb.jpg2018-11-06T05:47:53.000Z"054df5e3d47113fd88251bdf8006516d"12644STANDARD51/44eac.13.10.02.Appendix3B.pdf2018-11-04T23:51:29.000Z"27ce9ae01c0da7dc4b217f01590f3c41"170360STANDARD51/conversions/44eac.13.10.02.Appendix3B-thumb.jpg2018-11-06T05:47:54.000Z"767d52ab92e5df9e20e7291f23b7352c"9649STANDARD52/373bb.13.09.27.ResultsofMeeti.pdf2018-11-04T23:51:29.000Z"31331b85e6778d59de7661bac7afc584"94693STANDARD52/conversions/373bb.13.09.27.ResultsofMeeti-thumb.jpg2018-11-06T05:47:55.000Z"e38637590578c8f5c49dea7702590aea"4923STANDARD53/9b6bf.13.09.27.Appendix3Y-Stew.pdf2018-11-04T23:51:29.000Z"7b90fd4531d78e020cf7483c5db77324"22714STANDARD53/conversions/9b6bf.13.09.27.Appendix3Y-Stew-thumb.jpg2018-11-06T05:47:56.000Z"96359a36a120c3082c611eb4087e962e"12857STANDARD54/conversions/d3164.13.09.27.Appendix3Y-Ross-thumb.jpg2018-11-06T05:47:56.000Z"0b7daf3b49c7a70236ba90cb60005bf2"12827STANDARD54/d3164.13.09.27.Appendix3Y-Ross.pdf2018-11-04T23:51:29.000Z"894bfa33ee46dcee920061dbccc77882"22827STANDARD55/c504c.13.09.27.Appendix3B.pdf2018-11-04T23:51:29.000Z"bb0c2c578eed887a51713277f11becb2"171727STANDARD55/conversions/c504c.13.09.27.Appendix3B-thumb.jpg2018-11-06T05:47:57.000Z"7227c920825efedaee6b05da18365538"12687STANDARD56/ab364.13.09.26.NoticeofAnnual.pdf2018-11-04T23:51:30.000Z"d5fe3eba12f6b6e8528b612cfaaae24b"390152STANDARD56/conversions/ab364.13.09.26.NoticeofAnnual-thumb.jpg2018-11-06T05:47:58.000Z"86d43e976ebdfc8dc1aa2deaa4873c3b"7727STANDARD57/conversions/f20be.13.09.26.AnnualReportto-thumb.jpg2018-11-06T05:47:59.000Z"eb4a1312e17294a03f5277b4dbbf97e1"3982STANDARD57/f20be.13.09.26.AnnualReportto.pdf2018-11-04T23:51:30.000Z"2a2e0ff9edad62fc5dd1546890e2da38"2294031STANDARD58/76902.13.09.24.ECQExercisesOp.pdf2018-11-04T23:51:31.000Z"952c034f33bf79e38b388dee7ebf3f40"116710STANDARD58/conversions/76902.13.09.24.ECQExercisesOp-thumb.jpg2018-11-06T05:48:00.000Z"66d336f7e4ab00fee1f14139c5ea4748"4919STANDARD59/59312.13.09.24.ChairmanLetter.pdf2018-11-04T23:51:32.000Z"02a96f7c1c0230637fe5878347ef7c99"636521STANDARD59/conversions/59312.13.09.24.ChairmanLetter-thumb.jpg2018-11-06T05:48:01.000Z"c61dc0d043db466c535485715871e466"5402STANDARD6/58b90.13.08.07Section708ANot.pdf2018-11-04T23:51:17.000Z"cdd27e58e081eec2fe825e004b81fc04"86295STANDARD6/conversions/58b90.13.08.07Section708ANot-thumb.jpg2018-11-06T05:47:17.000Z"4f385d4defb6746cf2df7f3d98f71d0e"6949STANDARD60/7b83c.13.10.03.Section708ANot.pdf2018-11-04T23:51:32.000Z"461d23907342691cf65db7301017aab4"84899STANDARD60/conversions/7b83c.13.10.03.Section708ANot-thumb.jpg2018-11-06T05:48:01.000Z"9f7bd4e71cc2bbe29d665b60e074d51a"5241STANDARD61/3cf77.EcoQuestLtdProspectus.pdf2018-11-04T23:51:32.000Z"ae1b88d34e329cc0aa1dac7fa723fc1d"2555222STANDARD61/conversions/3cf77.EcoQuestLtdProspectus-thumb.jpg2018-11-06T05:48:03.000Z"f4636173a904e7d1b42ffb5a3155b6bc"12941STANDARD62/conversions/dc63d.13.11.26.CynataCo-Founde-thumb.jpg2018-11-06T05:48:04.000Z"7a61af1deb4821f0c8974993b8206cab"15987STANDARD62/dc63d.13.11.26.CynataCo-Founde.pdf2018-11-04T23:51:33.000Z"b01aac260e2e519dc5f15c48989cdd03"1126246STANDARD63/60e81.13.11.22.ConditionalRein.pdf2018-11-04T23:51:34.000Z"e54056b051d9ae5ba87eb76b98a43320"70832STANDARD63/conversions/60e81.13.11.22.ConditionalRein-thumb.jpg2018-11-06T05:48:05.000Z"03ed6e5c42f3de5ef771e7e15df566f0"11805STANDARD64/9b6b0.13.11.18ChangeofName.pdf2018-11-04T23:51:34.000Z"2d3a0ac6bea6983f3a0279dee454615a"69457STANDARD64/conversions/9b6b0.13.11.18ChangeofName-thumb.jpg2018-11-06T05:48:05.000Z"a407ad8061f597194f9a312cb5229181"13664STANDARD65/cf605.13.11.14.Appendix3Y-Ross.pdf2018-11-04T23:51:34.000Z"cc703cb65321bbe38097d6980bf8ea99"23026STANDARD65/conversions/cf605.13.11.14.Appendix3Y-Ross-thumb.jpg2018-11-06T05:48:06.000Z"efab883744c0b070ea76c89d8b298245"13006STANDARD66/27850.13.11.14.Appendix3YPete.pdf2018-11-04T23:51:34.000Z"e0e7d6b0e8dbe1f6be18dbb92eb5f0e8"24758STANDARD66/conversions/27850.13.11.14.Appendix3YPete-thumb.jpg2018-11-06T05:48:07.000Z"3896d244dc0b502c3b52c7c3afc7ee7e"13586STANDARD67/4b940.13.11.14.Appendix3Y-Ho.pdf2018-11-04T23:51:34.000Z"a07ce24339c5065e8149b3d6bc0b2c66"24220STANDARD67/conversions/4b940.13.11.14.Appendix3Y-Ho-thumb.jpg2018-11-06T05:48:07.000Z"9991e9f0cd7bea1477b21810b5bb4d0c"13298STANDARD68/01a59.13.11.27Appendix1AASX.pdf2018-11-04T23:51:34.000Z"8368444d5cc1a5345896265957c86b3f"464505STANDARD68/conversions/01a59.13.11.27Appendix1AASX-thumb.jpg2018-11-06T05:48:09.000Z"18bb76dae34a7f55a87f94fc9e18721d"14947STANDARD69/3db31.13.11.27ASXCircular-R.pdf2018-11-04T23:51:34.000Z"ccf82c6df2c29b1a4e26052f7e07cbd2"43925STANDARD69/conversions/3db31.13.11.27ASXCircular-R-thumb.jpg2018-11-06T05:48:09.000Z"186db1890302a8e4a77aa986cb86ccdc"9800STANDARD7/bf724.13.08.01PlacementSPP.pdf2018-11-04T23:51:17.000Z"bba45a498958ea9d2da1d12bbc653474"178777STANDARD7/conversions/bf724.13.08.01PlacementSPP-thumb.jpg2018-11-06T05:47:18.000Z"dc49833620ef14e75769c3b373b682e1"6626STANDARD70/a303c.13.11.27ASXListingInfo.pdf2018-11-04T23:51:34.000Z"fa35e5be0c3a473c429af86efc963236"136700STANDARD70/conversions/a303c.13.11.27ASXListingInfo-thumb.jpg2018-11-06T05:48:10.000Z"0b123682100596ea800debfdf11b82c5"13485STANDARD71/conversions/d7805.13.11.27CapitalStructur-thumb.jpg2018-11-06T05:48:11.000Z"4412e66f880e810de76e74994e9341aa"15842STANDARD71/d7805.13.11.27CapitalStructur.pdf2018-11-04T23:51:34.000Z"d7f0306a6e2dd65ef8f6fecdcd382d56"70684STANDARD72/7299e.13.11.27DistributionSch.pdf2018-11-04T23:51:35.000Z"b0dc0899c5d46b830302a25b25e0621c"96584STANDARD72/conversions/7299e.13.11.27DistributionSch-thumb.jpg2018-11-05T09:21:14.000Z"81dc8c0887331f5cf634911afb4f6f1f"14684STANDARD73/242c9.13.11.27GeneralPre-Rein.pdf2018-11-04T23:51:35.000Z"f47b4ff13cb111ad0091c226a52a90a5"69096STANDARD73/conversions/242c9.13.11.27GeneralPre-Rein-thumb.jpg2018-11-05T09:21:14.000Z"0a3c47fa96bae8207df51d01fbed9e26"14268STANDARD74/b1fbd.13.11.27Pre-Reinstatemen.pdf2018-11-04T23:51:35.000Z"4a981e268b4dd8d04c5c72ff94509fe8"23392STANDARD74/conversions/b1fbd.13.11.27Pre-Reinstatemen-thumb.jpg2018-11-05T09:21:15.000Z"dc011fa1b2d4afeed542d133c4a58378"5575STANDARD75/4f0f3.13.11.27Reinstatementto.pdf2018-11-04T23:51:35.000Z"c9c2eb4091eb996d370d33ada506adb1"22045STANDARD75/conversions/4f0f3.13.11.27Reinstatementto-thumb.jpg2018-11-05T09:21:16.000Z"52a55a24df50f0f2e2cb4b82cf69b996"5556STANDARD76/bd1fb.13.11.27RestrictedSecur.pdf2018-11-04T23:51:35.000Z"00a1bdf07e066160784dc85c7bd3d55e"70563STANDARD76/conversions/bd1fb.13.11.27RestrictedSecur-thumb.jpg2018-11-05T09:21:17.000Z"f9d56c3d75e91d38b3b6b692a1a9d38e"14751STANDARD77/bc886.13.11.27TermsConditio.pdf2018-11-04T23:51:35.000Z"08169d188151007d1ddeabf31331bb50"104723STANDARD77/conversions/bc886.13.11.27TermsConditio-thumb.jpg2018-11-05T09:21:18.000Z"f84234871dd06b00afd988c9094840c2"19278STANDARD78/0cb02.13.11.27UpdatedStatemen.pdf2018-11-04T23:51:35.000Z"e3e28bb86d2fc80d9ddfbd48b7ad9b22"70940STANDARD78/conversions/0cb02.13.11.27UpdatedStatemen-thumb.jpg2018-11-05T09:21:18.000Z"03889c2d1a1948fd3f542c52ae3fa9c4"14860STANDARD79/56720.13.11.27UpdatedStatemen.pdf2018-11-04T23:51:36.000Z"83392a1d2f0d26bf507b1861ccd13c4b"128799STANDARD79/conversions/56720.13.11.27UpdatedStatemen-thumb.jpg2018-11-05T09:21:19.000Z"607098ba11b7e60ba9a221bec2a7c2d1"10589STANDARD8/11df2.13.08.01NoticeUnderASI.pdf2018-11-04T23:51:17.000Z"0068b96d71b3921dd1f01fcc2def2a7f"84749STANDARD8/conversions/11df2.13.08.01NoticeUnderASI-thumb.jpg2018-11-06T05:47:19.000Z"ac8114ab166334756e8c4d98d65daac4"7009STANDARD80/56720.13.11.27UpdatedStatemen.pdf2018-11-04T23:51:36.000Z"83392a1d2f0d26bf507b1861ccd13c4b"128799STANDARD80/conversions/56720.13.11.27UpdatedStatemen-thumb.jpg2018-11-05T09:21:20.000Z"607098ba11b7e60ba9a221bec2a7c2d1"10589STANDARD81/9374a.13.11.29.NoticeofCeasin.pdf2018-11-04T23:51:36.000Z"8b136a3b56cf3d0d2f04252fb4f26ef0"1325414STANDARD81/conversions/9374a.13.11.29.NoticeofCeasin-thumb.jpg2018-11-05T09:21:21.000Z"473141eb74dfaf2dd58e7111d0db02e5"11214STANDARD82/2173e.13.12.02.Appendix3Y-Pe.pdf2018-11-04T23:51:37.000Z"25eb0e9babf4b92d964b064469e7e8ef"24194STANDARD82/conversions/2173e.13.12.02.Appendix3Y-Pe-thumb.jpg2018-11-05T09:21:22.000Z"a5e83809aa5dd90487006dd652e98654"13659STANDARD83/6ee69.13.12.02.ExpiryofUnlist.pdf2018-11-04T23:51:37.000Z"50b38f59773051ec49fcb26d903ee5d1"97237STANDARD83/conversions/6ee69.13.12.02.ExpiryofUnlist-thumb.jpg2018-11-05T09:21:23.000Z"c15f2b8ca0e962d1380c1ff16a7888cd"12353STANDARD84/96852.13.12.17.Appendix3B-Exer.pdf2018-11-04T23:51:38.000Z"2d0f03ba3acf5beebe685b1309caf77b"170203STANDARD84/conversions/96852.13.12.17.Appendix3B-Exer-thumb.jpg2018-11-05T09:21:23.000Z"64bc8131bfc3aefba5c73b31c84aff12"9641STANDARD85/90196.13.12.18.Section708ANot.pdf2018-11-04T23:51:38.000Z"a70dceb6e0480b7ff897fff4a752d314"98962STANDARD85/conversions/90196.13.12.18.Section708ANot-thumb.jpg2018-11-05T09:21:24.000Z"cd7f53e7df2e2d5a8e4dfde511883764"13255STANDARD86/92090.13.12.19.Appendix3Y-Ho.pdf2018-11-04T23:51:38.000Z"fed29840f98ff40bb1101335ee32c98e"24210STANDARD86/conversions/92090.13.12.19.Appendix3Y-Ho-thumb.jpg2018-11-05T09:21:25.000Z"1f29b9bbb7c80d4d8d0658cd05eb30b4"13356STANDARD87/450f2.13.12.20.Appendix3Y-Stew.pdf2018-11-04T23:51:38.000Z"125b5fcaba579b6722ee45d2891c63b4"94057STANDARD87/conversions/450f2.13.12.20.Appendix3Y-Stew-thumb.jpg2018-11-05T09:21:25.000Z"15c54db171b30845b30107210cbdc17b"13626STANDARD88/9e0e0.14.01.16.ExperiencedStem.pdf2018-11-04T23:51:38.000Z"46316a9814bcb4e42dc4091b6b1b55bf"146195STANDARD88/conversions/9e0e0.14.01.16.ExperiencedStem-thumb.jpg2018-11-05T09:21:26.000Z"7158a8db4d8d582f1a711b63a8f3904c"19792STANDARD89/0bb6a.14.01.21.Appendix3B-Exer.pdf2018-11-04T23:51:38.000Z"2bf3b7ad7c61633139624f765498e95c"170515STANDARD89/conversions/0bb6a.14.01.21.Appendix3B-Exer-thumb.jpg2018-11-05T09:21:27.000Z"337a0f102894eee4e15a43fc6739e37d"9722STANDARD9/51437.13.08.01InitialDirector.pdf2018-11-04T23:51:17.000Z"d6ab53db9a7580bd5b8cbed99fb86f7d"14212STANDARD9/conversions/51437.13.08.01InitialDirector-thumb.jpg2018-11-06T05:47:19.000Z"7935bda639f393329882e24e57387485"4941STANDARD90/aa8ce.14.01.30.Appendix4C.pdf2018-11-04T23:51:38.000Z"7124e6b74893e16a36bb3439dda1ece9"160378STANDARD90/conversions/aa8ce.14.01.30.Appendix4C-thumb.jpg2018-11-05T09:21:28.000Z"069fc22a31757d94c1fc1dcee08b0bf3"10587STANDARD91/18e3b.14.02.10.CynataPartners.pdf2018-11-04T23:51:38.000Z"4c38fbba62106dbb3d4765f645568682"145591STANDARD91/conversions/18e3b.14.02.10.CynataPartners-thumb.jpg2018-11-05T09:21:29.000Z"d87bb8fe05a8ca5de0fd03fbdbe204d9"19175STANDARD92/cceed.14.02.12.InvestorPresent.pdf2018-11-04T23:51:39.000Z"f058f51d01e365561d73037556db5b07"1035435STANDARD92/conversions/cceed.14.02.12.InvestorPresent-thumb.jpg2018-11-05T09:21:30.000Z"df652410fc1f7504375048a190b83c02"13996STANDARD93/644b1.14.02.25.Appendix4DHa.pdf2018-11-04T23:51:39.000Z"fa3a6456cef3018704f5cf44454dfce3"601919STANDARD93/conversions/644b1.14.02.25.Appendix4DHa-thumb.jpg2018-11-05T09:21:31.000Z"2961d7edc2c7331ac8d3c1935d540c56"16443STANDARD94/96dc0.14.02.28.MrHowardDigby.pdf2018-11-04T23:51:39.000Z"8bc380790eb2124ea9e4e29deb1ca816"142821STANDARD94/conversions/96dc0.14.02.28.MrHowardDigby-thumb.jpg2018-11-05T09:21:32.000Z"7ab385941327a161b5728bb9207cd510"12122STANDARD95/3f2e0.14.03.04.Appendix3Y-Stew.pdf2018-11-04T23:51:40.000Z"575ed0af86bcc6a9e2e51b5ef09c7b70"24325STANDARD95/conversions/3f2e0.14.03.04.Appendix3Y-Stew-thumb.jpg2018-11-05T09:21:32.000Z"cb343d1e40f25f78d717ecc0b7bfec8a"14111STANDARD96/7e43e.14.03.05.CynataGvHDPart.pdf2018-11-04T23:51:40.000Z"e54004bdd94f253f8d71d77f5c7de42b"150779STANDARD96/conversions/7e43e.14.03.05.CynataGvHDPart-thumb.jpg2018-11-05T09:21:33.000Z"e8ff4ebc5b90160bf5e042a29670a7b5"18589STANDARD97/3327e.14.04.29.ActivitiesRepor.pdf2018-11-04T23:51:40.000Z"7b98fe9fbf244a026503f065d1fad405"281705STANDARD97/conversions/3327e.14.04.29.ActivitiesRepor-thumb.jpg2018-11-05T09:21:34.000Z"895d6b402fbcfb5a5fdd31bf7ab33a48"16186STANDARD98/3e3d3.14.05.13.CYPToParticipa.pdf2018-11-04T23:51:40.000Z"1b8ee36c77c47419b2b7e61c3a570e6c"144776STANDARD98/conversions/3e3d3.14.05.13.CYPToParticipa-thumb.jpg2018-11-05T09:21:35.000Z"9fca0b6fb2eea9cd1a6a9ca5973db940"16744STANDARD99/conversions/ec5fa.14.05.19.VestingofUnlis-thumb.jpg2018-11-05T09:21:36.000Z"2a7a904404361edc20f99767d05f4c81"12894STANDARD99/ec5fa.14.05.19.VestingofUnlis.pdf2018-11-04T23:51:40.000Z"89625eae058d58bf45d0ded709888a60"143327STANDARDfiles/2018-11-05T04:35:22.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDfiles/Cynata-GvHD-Video.mp42019-06-28T01:41:22.000Z"64578f0c4d7483515df212dfc5cea9df"19241710STANDARDfiles/Cynata-GvHD-Video.mp4_old2019-06-28T01:41:17.000Z"4216bbfe0693e0d700676bb3ed2a18c4"20249624STANDARDfiles/Cynata.mp42019-06-28T02:17:25.000Z"146469bc825f425d20e45a38c2ab9c57"18566264STANDARDfiles/Cynata.mp4_old2019-06-28T01:41:15.000Z"9f0a07ee7d8bd9498902aee5cccc3e41"28484298STANDARD